<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CAPECITABINE- capecitabine tablet, film coated </strong><br>American Health Packaging<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use capecitabine tablets USP safely and effectively.  See full prescribing information for capecitabine tablets USP.<br><br>CAPECITABINE tablets USP, for oral use<br>Initial U.S. Approval: 1998<br>
</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: CAPECITABINE-WARFARIN INTERACTION</h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<p class="Highlighta"><span class="Bold">Patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulants such as warfarin and phenprocoumon should have their anticoagulant response (INR or <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time) monitored frequently in order to adjust the anticoagulant dose accordingly. Altered coagulation parameters and/or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, have been reported during concomitant use.</span> </p>
<dl>
<dt>•</dt>
<dd><span class="Bold">Occurrence: Within several days and up to several months after initiating capecitabine therapy; may also be seen within 1 month after stopping capecitabine</span></dd>
<dt>•</dt>
<dd><span class="Bold">Predisposing factors: age&gt; 60 and diagnosis of cancer</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Dosage and Administration (<a href="#i4i_dosage_admin_id_4ee8b0f1-a394-4b39-bffd-95fdf45802a8">2</a>)                10/2014  </p>
<p class="Highlighta">Warnings and Precautions <br>(<a href="#i4i_section_id_fe5ba4ac-7b83-4d69-8099-9a3fab590cbe">5.1</a>, <a href="#i4i_section_id_919f9270-38d4-4bec-adf2-2c189ed728c4">5.2</a>, <a href="#i4i_section_id_e875c4a4-1f00-4636-9d9e-67850c7d12b2">5.5</a>, and <a href="#i4i_section_id_e065f01f-ec6b-4c74-81e0-38a6cbb534e9">5.7</a>)                              10/2014 </p>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: CAPECITABINE-WARFARIN INTERACTION</h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<p class="Highlighta"><span class="Bold">Patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulants such as warfarin and phenprocoumon should have their anticoagulant response (INR or <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time) monitored frequently in order to adjust the anticoagulant dose accordingly. Altered coagulation parameters and/or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, have been reported during concomitant use.</span> </p>
<dl>
<dt>•</dt>
<dd><span class="Bold">Occurrence: Within several days and up to several months after initiating capecitabine therapy; may also be seen within 1 month after stopping capecitabine</span></dd>
<dt>•</dt>
<dd><span class="Bold">Predisposing factors: age&gt; 60 and diagnosis of cancer</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Capecitabine Tablets USP are a nucleoside metabolic inhibitor with antineoplastic activity indicated for: </p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Adjuvant Colon Cancer</span> (<a href="#i4i_section_id_c7673c9e-5a57-4722-a980-a958134ab8c9">1.1</a>) <dl>
<dt>‒</dt>
<dd>Patients with Dukes' C colon cancer</dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold">Metastatic Colorectal Cancer </span>(<a href="#i4i_section_id_c7673c9e-5a57-4722-a980-a958134ab8c9">1.1</a>) <dl>
<dt>‒</dt>
<dd>First-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred</dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold">Metastatic Breast Cancer</span> (<a href="#i4i_section_id_cacb39e9-769d-4c3e-b508-06f0d3279633">1.2</a>) <dl>
<dt>‒</dt>
<dd>In combination with docetaxel after failure of prior anthracycline-containing therapy</dd>
<dt>‒</dt>
<dd>As monotherapy in patients resistant to both paclitaxel and an anthracycline-containing regimen</dd>
</dl>
</dd>
</dl>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>•</dt>
<dd>Take capecitabine tablets with water within 30 min after a meal (<a href="#i4i_dosage_admin_id_4ee8b0f1-a394-4b39-bffd-95fdf45802a8">2</a>)</dd>
<dt>•</dt>
<dd>Monotherapy: 1250 mg/m<span class="Sup">2</span> twice daily orally for 2 weeks followed by a one week rest period in 3-week cycles (<a href="#i4i_section_id_abac7a78-f033-483c-b1b6-62e859e46711">2.1</a>)</dd>
<dt>•</dt>
<dd>Adjuvant treatment is recommended for a total of 6 months (8 cycles) (<a href="#i4i_section_id_abac7a78-f033-483c-b1b6-62e859e46711">2.1</a>)</dd>
<dt>•</dt>
<dd>In combination with docetaxel, the recommended dose of capecitabine tablets is 1250 mg/m<span class="Sup">2</span> twice daily for 2 weeks followed by a 7-day rest period, combined with docetaxel at 75 mg/m<span class="Sup">2</span> as a 1-hour IV infusion every 3 weeks (<a href="#i4i_section_id_abac7a78-f033-483c-b1b6-62e859e46711">2.1</a>)</dd>
<dt>•</dt>
<dd>Capecitabine tablets dosage may need to be individualized to optimize patient management (<a href="#i4i_section_id_9d9aac28-13cc-4f1f-8a10-8665b23637ec">2.2</a>)</dd>
<dt>•</dt>
<dd>Reduce the dose of capecitabine tablets by 25% in patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (<a href="#i4i_section_id_7a50b455-b993-4e92-b221-516c5cb5017c">2.3</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Tablets: 150 mg and 500 mg (<a href="#i4i_dosage_form_strength_id_f863f9d5-2435-4908-912e-c66d0145f7e7">3</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Dihydropyrimidine dehydrogenase (DPD) deficiency (<a href="#i4i_section_id_4aa8cebe-6158-4f9f-9df7-fc8f66d0aa50">4.1</a>)</dd>
<dt>•</dt>
<dd>Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> (<a href="#i4i_section_id_9d899da5-6f48-43c0-91ad-a7a2c387a649">4.2</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> (<a href="#i4i_section_id_14df1c0d-a7a7-4541-a866-156096fb1d27">4.3</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Coagulopathy</span></span>: May result in <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Monitor anticoagulant response (e.g., INR) and adjust anticoagulant dose accordingly. (<a href="#i4i_section_id_fe5ba4ac-7b83-4d69-8099-9a3fab590cbe">5.1</a>)</dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></span>: May be severe. Interrupt capecitabine treatment immediately until <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> resolves or decreases to grade 1. Recommend standard antidiarrheal treatments. (<a href="#i4i_section_id_919f9270-38d4-4bec-adf2-2c189ed728c4">5.2</a>)</dd>
<dt>•</dt>
<dd>
<span class="Bold">Cardiotoxicity</span>: Common in patients with a prior history of <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>. (<a href="#i4i_section_id_557457a5-3c1d-422f-b7cd-59c2f045fdda">5.3</a>)</dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span> and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Failure</span></span>: Interrupt capecitabine treatment until <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> is corrected. Potential risk of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> secondary to <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>. Monitor and correct <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>. (<a href="#i4i_section_id_e875c4a4-1f00-4636-9d9e-67850c7d12b2">5.5</a>).</dd>
<dt>•</dt>
<dd>
<span class="Bold">Pregnancy</span>: Can cause fetal harm. Advise women of the potential risk to the fetus. (<a href="#i4i_section_id_2a5297ef-8968-495f-8a79-c46e46995e50">5.6</a>, <a href="#i4i_pregnancy_id_6c31851f-7b16-4a65-896d-d81df13fcc8c">8.1</a>)</dd>
<dt>•</dt>
<dd>
<span class="Bold">Mucocutaneous and Dermatologic Toxicity</span>: Severe mucocutaneous reactions, Steven-Johnson Syndrome (SJS) and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">Toxic Epidermal Necrolysis</span> (TEN), have been reported. Capecitabine should be permanently discontinued in patients who experience a severe mucocutaneous reaction during treatment. Capecitabine may induce hand-and-foot syndrome. Interrupt capecitabine treatment until the hand-and-foot syndrome event resolves or decreases in intensity. (<a href="#i4i_section_id_e065f01f-ec6b-4c74-81e0-38a6cbb534e9">5.7</a>)</dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span></span>: Interrupt capecitabine treatment immediately until the <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> resolves or decreases in intensity. (<a href="#i4i_section_id_e0a105bb-0dd1-44aa-ad42-a207f6a2cd04">5.8</a>)</dd>
<dt>•</dt>
<dd>
<span class="Bold">Hematologic</span>: Do not treat patients with neutrophil counts &lt; 1.5 × 10<span class="Sup">9</span>/L or thrombocyte counts &lt; 100 × 10<span class="Sup">9</span>/L. If grade 3 to 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> or <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> occurs, stop therapy until condition resolves. (<a href="#i4i_section_id_d760a521-8511-46be-82c5-ab1af0d4e5e4">5.9</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (≥ 30%) were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, hand-and-foot syndrome, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>/<span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span>. Other adverse reactions, including serious adverse reactions, have been reported. (<a href="#i4i_adverse_effects_id_ec51f75a-ee4b-4bb1-9683-a0cb174a42ba">6</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact TEVA USA, PHARMACOVIGILANCE at 1-866-832-8537 or drug.safety@tevapharm.com; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Anticoagulants: Monitor anticoagulant response (INR or <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time) frequently in order to adjust the anticoagulant dose as needed. (<a href="#_Ref">5.2</a>, <a href="#i4i_section_id_7565bfb6-a1ff-435c-8296-5b8e8145d18b">7.1</a>)</dd>
<dt>•</dt>
<dd>Phenytoin: Monitor phenytoin levels in patients taking capecitabine concomitantly with phenytoin. The phenytoin dose may need to be reduced. (<a href="#i4i_section_id_7565bfb6-a1ff-435c-8296-5b8e8145d18b">7.1</a>)</dd>
<dt>•</dt>
<dd>Leucovorin: The concentration of 5-fluorouracil is increased and its toxicity may be enhanced by leucovorin. (<a href="#i4i_section_id_7565bfb6-a1ff-435c-8296-5b8e8145d18b">7.1</a>)</dd>
<dt>•</dt>
<dd>CYP2C9 substrates: Care should be exercised when capecitabine is coadministered with CYP2C9 substrates. (<a href="#i4i_section_id_7565bfb6-a1ff-435c-8296-5b8e8145d18b">7.1</a>)</dd>
<dt>•</dt>
<dd>Food reduced both the rate and extent of absorption of capecitabine. (<a href="#i4i_dosage_admin_id_4ee8b0f1-a394-4b39-bffd-95fdf45802a8">2</a>, <a href="#i4i_section_id_7565bfb6-a1ff-435c-8296-5b8e8145d18b">7.1</a>, <a href="#i4i_pharmacokinetics_id_27d04e08-8b25-4fde-9ec6-60db982c0ff2">12.3</a>)</dd>
</dl></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>
<span class="Bold">Nursing Mothers</span>: Discontinue nursing when receiving capecitabine treatment. (<a href="#i4i_nursing_mothers_id_52abbfce-c22d-49d8-985e-e9f750ca9385">8.3</a>)</dd>
<dt>•</dt>
<dd>
<span class="Bold">Geriatric</span>: Greater incidence of adverse reactions. Monitoring required. (<a href="#i4i_geriatric_use_id_65c546e2-b758-44de-8240-f9dd6a917f2c">8.5</a>)</dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span>: Monitoring is recommended in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (<a href="#i4i_section_id_830efa38-0f3c-43d0-b537-521c325ae087">8.6</a>)</dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span>: Reduce capecitabine starting dose in patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (<a href="#i4i_section_id_7a50b455-b993-4e92-b221-516c5cb5017c">2.3</a>, <a href="#i4i_section_id_0e30f7d8-a584-4c73-8034-19dfcf434247">8.7</a>, <a href="#i4i_pharmacokinetics_id_27d04e08-8b25-4fde-9ec6-60db982c0ff2">12.3</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 10/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: CAPECITABINE-WARFARIN INTERACTION</a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Colorectal Cancer</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Breast Cancer</a></h2>
<h1><a href="#section-2" class="toc"><span class="XmChange">2 DOSAGE AND ADMINISTRATION</span></a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Standard Starting Dose</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dose Management Guidelines</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Adjustment of Starting Dose in Special Populations</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 Dihydropyrimidine Dehydrogenase (DPD) Deficiency</a></h2>
<h2><a href="#section-4.2" class="toc">4.2 Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-4.3" class="toc">4.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc"><span class="XmChange">5.1 <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Coagulopathy</span></span></a></h2>
<h2><a href="#section-5.2" class="toc"><span class="XmChange">5.2 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Cardiotoxicity </a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4299531" conceptname="Dihydrouracil dehydrogenase (NADP^+^) deficiency">Dihydropyrimidine Dehydrogenase Deficiency</span> </a></h2>
<h2><a href="#section-5.5" class="toc"><span class="XmChange">5.5 <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span> and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Failure</span></span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Pregnancy</a></h2>
<h2><a href="#section-5.7" class="toc"><span class="XmChange">5.7 Mucocutaneous and Dermatologic Toxicity</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span> </a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Hematologic </a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Geriatric Patients</a></h2>
<h2><a href="#section-5.11" class="toc">5.11 <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></a></h2>
<h2><a href="#section-5.12" class="toc">5.12 Combination With Other Drugs</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Adjuvant Colon Cancer</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Metastatic Colorectal Cancer</a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Breast Cancer </a></h2>
<h2><a href="#section-6.4" class="toc">6.4 Clinically Relevant Adverse Events in &lt; 5% of Patients</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Drug-Drug Interactions</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Drug-Food Interaction</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Adjuvant Colon Cancer</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Metastatic Colorectal Cancer</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Breast Cancer </a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="i4i_boxed_warning_id_d82ab764-9f72-4cc3-8bd2-f3d8cd97def7"></a><a name="section-1"></a><p></p>
<h1>WARNING: CAPECITABINE-WARFARIN INTERACTION</h1>
<p class="First"><span class="Bold">Capecitabine-Warfarin Interaction: Patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy should have their anticoagulant response (INR or <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time) monitored frequently in order to adjust the anticoagulant dose accordingly. A clinically important capecitabine-Warfarin drug interaction was demonstrated in a clinical pharmacology trial [<span class="Italics">see Warnings and Precautions (<a href="#_Ref">5.2</a>) and Drug Interactions (<a href="#i4i_section_id_7565bfb6-a1ff-435c-8296-5b8e8145d18b">7.1</a>)</span>]. Altered coagulation parameters and/or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon. Postmarketing reports have shown clinically significant increases in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time (PT) and INR in patients who were stabilized on anticoagulants at the time capecitabine was introduced. These events occurred within several days and up to several months after initiating capecitabine therapy and, in a few cases, within 1 month after stopping capecitabine. These events occurred in patients with and without liver <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>. Age greater than 60 and a diagnosis of cancer independently predispose patients to an increased risk of <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulopathy</span>.</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_38e46238-01c4-421b-854f-d3d3ccc719e8"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c7673c9e-5a57-4722-a980-a958134ab8c9"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Colorectal Cancer</h2>
<dl>
<dt>•</dt>
<dd>Capecitabine Tablets USP are indicated as a single agent for adjuvant treatment in patients with Dukes' C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. Capecitabine tablets USP were non-inferior to 5-fluorouracil and leucovorin (5-FU/LV) for disease-free survival (DFS). Physicians should consider results of combination chemotherapy trials, which have shown improvement in DFS and OS, when prescribing single-agent capecitabine tablets USP in the adjuvant treatment of Dukes' C colon cancer.</dd>
<dt>•</dt>
<dd>Capecitabine Tablets USP are indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. Combination chemotherapy has shown a survival benefit compared to 5-FU/LV alone. A survival benefit over 5-FU/LV has not been demonstrated with capecitabine tablets USP monotherapy. Use of capecitabine tablets USP instead of 5-FU/LV in combinations has not been adequately studied to assure safety or preservation of the survival advantage.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cacb39e9-769d-4c3e-b508-06f0d3279633"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Breast Cancer</h2>
<dl>
<dt>•</dt>
<dd>Capecitabine Tablets USP in combination with docetaxel are indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy.</dd>
<dt>•</dt>
<dd>Capecitabine Tablets USP monotherapy is also indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated (e.g., patients who have received cumulative doses of 400 mg/m<span class="Sup">2</span> of doxorubicin or doxorubicin equivalents). Resistance is defined as progressive disease while on treatment, with or without an initial response, or relapse within 6 months of completing treatment with an anthracycline-containing adjuvant regimen.</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_4ee8b0f1-a394-4b39-bffd-95fdf45802a8"></a><a name="section-2"></a><p></p>
<h1 style="border-left:1px solid;"><span class="XmChange">2 DOSAGE AND ADMINISTRATION</span></h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Capecitabine tablets should be swallowed whole with water within 30 minutes after a meal. Do not crush or cut capecitabine tablets. Capecitabine tablets dose is calculated according to body surface area.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_abac7a78-f033-483c-b1b6-62e859e46711"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Standard Starting Dose</h2>
<p class="First"><span class="Underline">Monotherapy (Metastatic Colorectal Cancer, Adjuvant Colorectal Cancer, Metastatic Breast Cancer) </span></p>
<p>The recommended dose of capecitabine tablets is 1250 mg/m<span class="Sup">2</span> administered orally twice daily (morning and evening; equivalent to 2500 mg/m<span class="Sup">2</span> total daily dose) for 2 weeks followed by a 1-week rest period given as 3-week cycles (see <span class="Bold"><a href="#_Ref429578454">Table 1</a></span>).</p>
<p>Adjuvant treatment in patients with Dukes' C colon cancer is recommended for a total of 6 months [i.e., capecitabine tablets 1250 mg/m<span class="Sup">2</span> orally twice daily for 2 weeks followed by a 1-week rest period, given as 3-week cycles for a total of 8 cycles (24 weeks)].</p>
<a name="_Ref429578454"></a><table width="100%">
<caption><span>Table 1: Capecitabine Tablets Dose Calculation According to Body Surface Area </span></caption>
<col width="25%">
<col width="25%">
<col width="25%">
<col width="25%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="4" valign="top">
<span class="Sup">1</span>  Total Daily Dose divided by 2 to allow equal morning and evening doses</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Dose Level 1250 mg/m<span class="Sup">2</span></span><br><span class="Bold">Twice a Day</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Number of Tablets to be Taken at <br>Each Dose (Morning and Evening)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">Surface Area (m<span class="Sup">2</span>)</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">Total Daily Dose</span><span class="Italics"><span class="Sup">1</span></span><span class="Bold"> (mg)</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">150 mg</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">500 mg</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">≤ 1.25</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">3000</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.26 to 1.37</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">3300</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.38 to 1.51</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">3600</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.52 to 1.65</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">4000</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.66 to 1.77</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">4300</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.78 to 1.91</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">4600</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.92 to 2.05</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">5000</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2.06 to 2.17</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">5300</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">5</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center" valign="top"><p class="First">≥ 2.18</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">5600</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">5</p></td>
</tr>
</tbody>
</table>
<p><span class="Underline">In Combination With Docetaxel (Metastatic Breast Cancer)</span></p>
<p>In combination with docetaxel, the recommended dose of capecitabine tablets are 1250 mg/m<span class="Sup">2</span> twice daily for 2 weeks followed by a 1-week rest period, combined with docetaxel at 75 mg/m<span class="Sup">2</span> as a 1-hour intravenous infusion every 3 weeks. Pre-medication, according to the docetaxel labeling, should be started prior to docetaxel administration for patients receiving the capecitabine tablets plus docetaxel combination. <span class="Bold"><a href="#_Ref429578454">Table 1</a></span> displays the total daily dose of capecitabine tablets by body surface area and the number of tablets to be taken at each dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9d9aac28-13cc-4f1f-8a10-8665b23637ec"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dose Management Guidelines</h2>
<p class="First"><span class="Underline">General</span></p>
<p>Capecitabine tablets dosage may need to be individualized to optimize patient management. Patients should be carefully monitored for toxicity and doses of capecitabine tablets should be modified as necessary to accommodate individual patient tolerance to treatment [<span class="Italics">see Clinical Studies (<a href="#i4i_clinical_studies_id_677a91a9-95f6-4df1-9a4c-ad95463fca55">14</a>)</span>]. Toxicity due to capecitabine tablet administration may be managed by symptomatic treatment, dose interruptions and adjustment of capecitabine tablets dose. Once the dose has been reduced, it should not be increased at a later time. Doses of capecitabine tablets omitted for toxicity are not replaced or restored; instead the patient should resume the planned treatment cycles.</p>
<p>The dose of phenytoin and the dose of coumarin-derivative anticoagulants may need to be reduced when either drug is administered concomitantly with capecitabine tablets [<span class="Italics">see Drug Interactions (<a href="#i4i_section_id_7565bfb6-a1ff-435c-8296-5b8e8145d18b">7.1</a>)</span>].</p>
<p><span class="Underline">Monotherapy (Metastatic Colorectal Cancer, Adjuvant Colorectal Cancer, Metastatic Breast Cancer)</span></p>
<p>Capecitabine tablets dose modification scheme as described below (see <span class="Bold"><a href="#_Ref429578757">Table 2</a></span>) is recommended for the management of adverse reactions.</p>
<a name="_Ref429578757"></a><table width="100%">
<caption><span>Table 2: Recommended Dose Modifications of Capecitabine Tablets </span></caption>
<col width="17%">
<col width="41%">
<col width="43%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="3" valign="top">
<span class="Sup">1</span>  National Cancer Institute of Canada Common Toxicity Criteria were used except for the hand-and-foot syndrome [<span class="Italics">see Warnings and Precautions (<a href="#i4i_warnings_precautions_id_32de6a8d-14ca-4473-b8a5-6f08739ee537">5</a>)</span>].</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Toxicity NCIC Grades</span><span class="Italics"><span class="Sup">1</span></span></p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First"><br><span class="Bold"> During a Course of Therapy</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Dose Adjustment for Next Treatment (% of starting dose)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Italics">Grade 1</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Italics">Maintain dose level</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Italics">Maintain dose level</span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3" valign="top"><p class="First"><span class="Italics">Grade 2</span></p></td></tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">-1st appearance</p></td>
<td class="Botrule Lrule" align="center" rowspan="3" valign="top"><p class="First">Interrupt until resolved to grade 0 to 1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">100%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">-2nd appearance</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">75%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">-3rd appearance</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">-4th appearance</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">Discontinue treatment permanently</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3" valign="top"><p class="First"><span class="Italics">Grade 3</span></p></td></tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">-1st appearance</p></td>
<td class="Botrule Lrule" align="center" rowspan="2" valign="top"><p class="First">Interrupt until resolved to grade 0 to 1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">75%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">-2nd appearance</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">-3rd appearance</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">Discontinue treatment permanently</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3" valign="top"><p class="First"><span class="Italics">Grade 4</span></p></td></tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First">-1st appearance</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">Discontinue permanently<br>OR<br>If physician deems it to be in the patient's best interest to continue, interrupt until resolved to grade 0 to 1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50%</p></td>
</tr>
</tbody>
</table>
<p><span class="Underline">In Combination With Docetaxel (Metastatic Breast Cancer)</span></p>
<p>Dose modifications of capecitabine tablets for toxicity should be made according to <span class="Bold"><a href="#_Ref429578757">Table 2</a></span> above for capecitabine tablets. At the beginning of a treatment cycle, if a treatment delay is indicated for either capecitabine tablets or docetaxel, then administration of both agents should be delayed until the requirements for restarting both drugs are met.</p>
<p>The dose reduction schedule for docetaxel when used in combination with capecitabine tablets for the treatment of metastatic breast cancer is shown in <span class="Bold"><a href="#_Ref429645546">Table 3</a></span>.</p>
<a name="_Ref429645546"></a><table width="100%">
<caption><span>Table 3: Docetaxel Dose Reduction Schedule in Combination with Capecitabine Tablets </span></caption>
<col width="17%">
<col width="33%">
<col width="32%">
<col width="18%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="7" valign="top">
<span class="Sup">1</span>  National Cancer Institute of Canada Common Toxicity Criteria were used except for hand-and-foot syndrome [<span class="Italics">see Warnings and Precautions (<a href="#i4i_warnings_precautions_id_32de6a8d-14ca-4473-b8a5-6f08739ee537">5</a>)</span>].</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"><p class="First"><span class="Bold">Toxicity NCIC Grades</span><span class="Italics"><span class="Sup">1</span></span></p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Grade 2</span></p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Grade 3</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Grade 4</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">1st appearance</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">Delay treatment until resolved to grade 0 to 1; Resume treatment with original dose of 75 mg/m<span class="Sup">2</span> docetaxel</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">Delay treatment until resolved to grade 0 to 1; Resume treatment at 55 mg/m<span class="Sup">2</span> of docetaxel.</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Discontinue treatment with docetaxel</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">2nd appearance</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">Delay treatment until resolved to grade 0 to 1; Resume treatment at 55 mg/m<span class="Sup">2</span> of docetaxel.</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">Discontinue treatment with docetaxel</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First">3rd appearance</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">Discontinue treatment with docetaxel</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7a50b455-b993-4e92-b221-516c5cb5017c"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Adjustment of Starting Dose in Special Populations</h2>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>No adjustment to the starting dose of capecitabine tablets is recommended in patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance = 51 to 80 mL/min [Cockroft and Gault, as shown below]). In patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (baseline creatinine clearance = 30 to 50 mL/min), a dose reduction to 75% of the capecitabine tablets starting dose when used as monotherapy or in combination with docetaxel (from 1250 mg/m<span class="Sup">2</span> to 950 mg/m<span class="Sup">2</span> twice daily) is recommended [<span class="Italics">see Use in Specific Populations (<a href="#i4i_section_id_0e30f7d8-a584-4c73-8034-19dfcf434247">8.7</a>) and Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_27d04e08-8b25-4fde-9ec6-60db982c0ff2">12.3</a>)</span>]. Subsequent dose adjustment is recommended as outlined in <span class="Bold"><a href="#_Ref429578757">Table 2</a></span> and <span class="Bold"><a href="#_Ref429645546">Table 3</a></span> (depending on the regimen) if a patient develops a grade 2 to 4 adverse event [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_e875c4a4-1f00-4636-9d9e-67850c7d12b2">5.5</a>)</span>]. The starting dose adjustment recommendations for patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> apply to both capecitabine tablets monotherapy and capecitabine tablets in combination use with docetaxel.</p>
<table width="100%">
<col width="36%">
<col width="64%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"><p class="First">Cockroft and Gault Equation:</p></td>
<td class="Toprule" valign="top"></td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top"><p class="First"> (140 - age [yrs]) (body wt [kg])</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Creatinine clearance for males = </p></td>
<td valign="top"><p class="First">—————————————</p></td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top"><p class="First">(72) (serum creatinine [mg/dL])</p></td>
</tr>
<tr>
<td valign="top"><p class="First"> </p></td>
<td valign="top"><p class="First"> </p></td>
</tr>
<tr class="Last"><td class="Botrule" colspan="2" valign="top"><p class="First">Creatinine clearance for females = 0.85 × male value</p></td></tr>
</tbody>
</table>
<p><br><span class="Underline">Geriatrics</span></p>
<p>Physicians should exercise caution in monitoring the effects of capecitabine tablets in the elderly. Insufficient data are available to provide a dosage recommendation.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_f863f9d5-2435-4908-912e-c66d0145f7e7"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">150 mg: Peach to light peach, oblong, film-coated, biconvex, unscored tablets, debossed with 190 on one side and 77 on the other side.</p>
<p>500 mg: Peach to light peach, oblong, film-coated, biconvex, unscored tablets debossed with 191 on one side and 77 on the other side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_22e98f36-a120-4c00-9d5b-1ad235d637de"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4aa8cebe-6158-4f9f-9df7-fc8f66d0aa50"></a><a name="section-4.1"></a><p></p>
<h2>4.1 Dihydropyrimidine Dehydrogenase (DPD) Deficiency</h2>
<p class="First">Capecitabine is contraindicated in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9d899da5-6f48-43c0-91ad-a7a2c387a649"></a><a name="section-4.2"></a><p></p>
<h2>4.2 Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Capecitabine is contraindicated in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance below 30 mL/min [Cockroft and Gault]) [<span class="Italics">see Use in Specific Populations (<a href="#i4i_section_id_0e30f7d8-a584-4c73-8034-19dfcf434247">8.7</a>)</span> and <span class="Italics">Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_27d04e08-8b25-4fde-9ec6-60db982c0ff2">12.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_14df1c0d-a7a7-4541-a866-156096fb1d27"></a><a name="section-4.3"></a><p></p>
<h2>4.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">Capecitabine is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to capecitabine or to any of its components. Capecitabine is contraindicated in patients who have a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to 5-fluorouracil.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_32de6a8d-14ca-4473-b8a5-6f08739ee537"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<p class="First"><span class="Underline">General</span></p>
<p>Patients receiving therapy with capecitabine should be monitored by a physician experienced in the use of cancer chemotherapeutic agents. Most adverse reactions are reversible and do not need to result in discontinuation, although doses may need to be withheld or reduced [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_9d9aac28-13cc-4f1f-8a10-8665b23637ec">2.2</a>)</span>].</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fe5ba4ac-7b83-4d69-8099-9a3fab590cbe"></a><a name="section-5.1"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">5.1 <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Coagulopathy</span></span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy should have their anticoagulant response (INR or <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time) monitored closely with great frequency and the anticoagulant dose should be adjusted accordingly [<span class="Italics">see <a href="#i4i_boxed_warning_id_d82ab764-9f72-4cc3-8bd2-f3d8cd97def7">Boxed Warning</a> and Drug Interactions (<a href="#i4i_section_id_7565bfb6-a1ff-435c-8296-5b8e8145d18b">7.1</a>)</span>]</span><span class="Italics">.   </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_919f9270-38d4-4bec-adf2-2c189ed728c4"></a><a name="section-5.2"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">5.2 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Capecitabine can induce <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, sometimes severe. Patients with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated. In 875 patients with either metastatic breast or colorectal cancer who received capecitabine monotherapy, the median time to first occurrence of grade 2 to 4 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> was 34 days (range from 1 to 369 days). The median duration of grade 3 to 4 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> was 5 days. National Cancer Institute of Canada (NCIC) grade 2 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> is defined as an increase of 4 to 6 stools/day or nocturnal stools, grade 3 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> as an increase of 7 to 9 stools/day or <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span> and <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption</span>, and grade 4 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> as an increase of ≥10 stools/day or grossly <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span> or the need for parenteral support. If grade 2, 3 or 4 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs, administration of capecitabine should be immediately interrupted until the <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> resolves or decreases in intensity to grade 1 [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_9d9aac28-13cc-4f1f-8a10-8665b23637ec">2.2</a>)</span>]. Standard antidiarrheal treatments (e.g., loperamide) are recommended.</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="201957" conceptname="Necrotizing enterocolitis in fetus OR newborn">Necrotizing enterocolitis</span> (<span class="product-label-link" type="condition" conceptid="4189378" conceptname="Typhlitis">typhlitis</span>) has been reported.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_557457a5-3c1d-422f-b7cd-59c2f045fdda"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Cardiotoxicity </h2>
<p class="First">The cardiotoxicity observed with capecitabine includes <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>/<span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, angina, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">dysrhythmias</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>, electrocardiographic changes, and <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>. These adverse reactions may be more common in patients with a prior history of <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_91f0942d-f720-4b2a-8cbb-21b702a62848"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4299531" conceptname="Dihydrouracil dehydrogenase (NADP^+^) deficiency">Dihydropyrimidine Dehydrogenase Deficiency</span> </h2>
<p class="First">Rarely, unexpected, severe toxicity (e.g., <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>) associated with 5-fluorouracil has been attributed to a deficiency of dihydropyrimidine dehydrogenase (DPD) activity. A link between decreased levels of DPD and increased, potentially fatal toxic effects of 5-fluorouracil therefore cannot be excluded.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e875c4a4-1f00-4636-9d9e-67850c7d12b2"></a><a name="section-5.5"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">5.5 <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span> and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Failure</span></span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span> has been observed and may cause <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> which can be fatal. Patients with pre-existing compromised renal function or who are receiving concomitant capecitabine with known nephrotoxic agents are at higher risk. Patients with <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> may rapidly become dehydrated. Monitor patients when capecitabine is administered to prevent and correct <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> at the onset. If grade 2 (or higher) <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> occurs, capecitabine treatment should be immediately interrupted and the <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> corrected. Treatment should not be restarted until the patient is rehydrated and any precipitating causes have been corrected or controlled. Dose modifications should be applied for the precipitating adverse event as necessary [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_9d9aac28-13cc-4f1f-8a10-8665b23637ec">2.2</a>)</span>]. </span></p>
<p style="border-left:1px solid;"><span class="XmChange">Patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> at baseline require dose reduction [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_7a50b455-b993-4e92-b221-516c5cb5017c">2.3</a>)</span>]. Patients with mild and moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> at baseline should be carefully monitored for adverse reactions. Prompt interruption of therapy with subsequent dose adjustments is recommended if a patient develops a grade 2 to 4 adverse event as outlined in <span class="Bold"><a href="#_Ref429578757">Table 2</a></span> <span class="Italics">[see Dosage and Administration (<a href="#i4i_section_id_9d9aac28-13cc-4f1f-8a10-8665b23637ec">2.2</a>), Use in Specific Populations (<a href="#i4i_section_id_0e30f7d8-a584-4c73-8034-19dfcf434247">8.7</a>), and Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_27d04e08-8b25-4fde-9ec6-60db982c0ff2">12.3</a>)]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2a5297ef-8968-495f-8a79-c46e46995e50"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Pregnancy</h2>
<p class="First">Capecitabine may cause fetal harm when given to a pregnant woman. Capecitabine caused embryolethality and <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> in mice and embryolethality in monkeys when administered during organogenesis. If this drug is used during pregnancy, or if a patient becomes pregnant while receiving capecitabine, the patient should be apprised of the potential hazard to the fetus [<span class="Italics">see Use in Specific Populations (<a href="#i4i_pregnancy_id_6c31851f-7b16-4a65-896d-d81df13fcc8c">8.1</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e065f01f-ec6b-4c74-81e0-38a6cbb534e9"></a><a name="section-5.7"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">5.7 Mucocutaneous and Dermatologic Toxicity</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Severe mucocutaneous reactions, some with fatal outcome, such as <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">Toxic Epidermal Necrolysis</span> (TEN) can occur in patients treated with capecitabine [<span class="Italics">see Adverse Reactions (<a href="#i4i_section_id_d2239c42-247d-4a23-a25b-0d3732a51e27">6.4</a>)</span>]. Capecitabine should be permanently discontinued in patients who experience a severe mucocutaneous reaction possibly attributable to capecitabine treatment. </span></p>
<p style="border-left:1px solid;"><span class="XmChange">Hand-and-foot syndrome (palmar-plantar erythrodysesthesia or chemotherapy-induced acral <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>) is a cutaneous toxicity. Median time to onset was 79 days (range from 11 to 360 days) with a severity range of grades 1 to 3 for patients receiving capecitabine monotherapy in the metastatic setting. Grade 1 is characterized by any of the following: <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesia</span>/<span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, painless <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> of the hands and/or feet and/or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> which does not disrupt normal activities. Grade 2 hand-and-foot syndrome is defined as painful <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the hands and/or feet and/or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> affecting the patient’s activities of daily living. Grade 3 hand-and-foot syndrome is defined as moist <span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">desquamation</span>, ulceration, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span> or severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> of the hands and/or feet and/or severe <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> that causes the patient to be unable to work or perform activities of daily living. If grade 2 or 3 hand-and-foot syndrome occurs, administration of capecitabine should be interrupted until the event resolves or decreases in intensity to grade 1. Following grade 3 hand-and-foot syndrome, subsequent doses of capecitabine should be decreased <span class="Italics">[see Dosage and Administration (<a href="#i4i_section_id_9d9aac28-13cc-4f1f-8a10-8665b23637ec">2.2</a>)]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e0a105bb-0dd1-44aa-ad42-a207f6a2cd04"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span> </h2>
<p class="First">In 875 patients with either metastatic breast or colorectal cancer who received at least one dose of capecitabine 1250 mg/m<span class="Sup">2</span> twice daily as monotherapy for 2 weeks followed by a 1-week rest period, grade 3 (1.5 to 3 × ULN) <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> occurred in 15.2% (n = 133) of patients and grade 4 (&gt; 3 × ULN) <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> occurred in 3.9% (n = 34) of patients. Of 566 patients who had hepatic <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> at baseline and 309 patients without hepatic <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> at baseline, grade 3 or 4 <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> occurred in 22.8% and 12.3%, respectively. Of the 167 patients with grade 3 or 4 <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span>, 18.6% (n = 31) also had postbaseline elevations (grades 1 to 4, without elevations at baseline) in alkaline phosphatase and 27.5% (n = 46) had postbaseline elevations in transaminases at any time (not necessarily concurrent). The majority of these patients, 64.5% (n = 20) and 71.7% (n = 33), had liver <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> at baseline. In addition, 57.5% (n = 96) and 35.3% (n = 59) of the 167 patients had elevations (grades 1 to 4) at both prebaseline and postbaseline in alkaline phosphatase or transaminases, respectively. Only 7.8% (n = 13) and 3% (n = 5) had grade 3 or 4 elevations in alkaline phosphatase or transaminases.</p>
<p>In the 596 patients treated with capecitabine as first-line therapy for metastatic colorectal cancer, the incidence of grade 3 or 4 <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> was similar to the overall clinical trial safety database of capecitabine monotherapy. The median time to onset for grade 3 or 4 <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> in the colorectal cancer population was 64 days and median total bilirubin increased from 8 µm/L at baseline to 13 µm/L during treatment with capecitabine. Of the 136 colorectal cancer patients with grade 3 or 4 <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span>, 49 patients had grade 3 or 4 <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> as their last measured value, of which 46 had liver <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> at baseline.</p>
<p>In 251 patients with metastatic breast cancer who received a combination of capecitabine and docetaxel, grade 3 (1.5 to 3 × ULN) <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> occurred in 7% (n = 17) and grade 4 (&gt; 3 × ULN) <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> occurred in 2% (n = 5).</p>
<p>If drug-related grade 3 to 4 elevations in bilirubin occur, administration of capecitabine should be immediately interrupted until the <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> decreases to ≤ 3 × ULN [see recommended dose modifications under<span class="Italics"> Dosage and Administration (<a href="#i4i_section_id_9d9aac28-13cc-4f1f-8a10-8665b23637ec">2.2</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d760a521-8511-46be-82c5-ab1af0d4e5e4"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Hematologic </h2>
<p class="First">In 875 patients with either metastatic breast or colorectal cancer who received a dose of 1250 mg/m<span class="Sup">2</span> administered twice daily as monotherapy for 2 weeks followed by a 1-week rest period, 3.2%, 1.7%, and 2.4% of patients had grade 3 or 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> or decreases in hemoglobin, respectively. In 251 patients with metastatic breast cancer who received a dose of capecitabine in combination with docetaxel, 68% had grade 3 or 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, 2.8% had grade 3 or 4 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and 9.6% had grade 3 or 4 <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.</p>
<p>Patients with baseline neutrophil counts of &lt; 1.5 × 10<span class="Sup">9</span>/L and/or thrombocyte counts of &lt; 100 × 10<span class="Sup">9</span>/L should not be treated with capecitabine. If unscheduled laboratory assessments during a treatment cycle show grade 3 or 4 hematologic toxicity, treatment with capecitabine should be interrupted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c1e475d4-85d1-48e1-8b17-cbeecada244d"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Geriatric Patients</h2>
<p class="First">Patients ≥ 80 years old may experience a greater incidence of grade 3 or 4 adverse reactions. In 875 patients with either metastatic breast or colorectal cancer who received capecitabine monotherapy, 62% of the 21 patients ≥ 80 years of age treated with capecitabine experienced a treatment-related grade 3 or 4 adverse event: <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> in 6 (28.6%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> in 3 (14.3%), hand-and-foot syndrome in 3 (14.3%), and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> in 2 (9.5%) patients. Among the 10 patients 70 years of age and greater (no patients were &gt; 80 years of age) treated with capecitabine in combination with docetaxel, 30% (3 out of 10) of patients experienced grade 3 or 4 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, and 40% (4 out of 10) experienced grade 3 hand-and-foot syndrome.</p>
<p>Among the 67 patients ≥ 60 years of age receiving capecitabine in combination with docetaxel, the incidence of grade 3 or 4 treatment-related adverse reactions, treatment-related serious adverse reactions, withdrawals due to adverse reactions, treatment discontinuations due to adverse reactions and treatment discontinuations within the first two treatment cycles was higher than in the &lt; 60 years of age patient group.</p>
<p>In 995 patients receiving capecitabine as adjuvant therapy for Dukes' C colon cancer after resection of the primary tumor, 41% of the 398 patients ≥ 65 years of age treated with capecitabine experienced a treatment-related grade 3 or 4 adverse event: hand-and-foot syndrome in 75 (18.8%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> in 52 (13.1%), <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> in 12 (3%), <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>/<span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span> in 11 (2.8%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> in 6 (1.5%), and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> in 5 (1.3%) patients. In patients ≥ 65 years of age (all randomized population; capecitabine 188 patients, 5-FU/LV 208 patients) treated for Dukes' C colon cancer after resection of the primary tumor, the hazard ratios for disease-free survival and overall survival for capecitabine compared to 5-FU/LV were 1.01 (95% C.I. 0.80  to 1.27) and 1.04 (95% C.I. 0.79 to 1.37), respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ea741bb7-3bb6-4dc2-8b43-f05175530c4b"></a><a name="section-5.11"></a><p></p>
<h2>5.11 <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></h2>
<p class="First">Patients with mild to moderate hepatic dysfunction due to liver <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> should be carefully monitored when capecitabine is administered. The effect of severe hepatic dysfunction on the disposition of capecitabine is not known [<span class="Italics">see Use in Specific Populations (<a href="#i4i_section_id_830efa38-0f3c-43d0-b537-521c325ae087">8.6</a>)</span> and <span class="Italics">Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_27d04e08-8b25-4fde-9ec6-60db982c0ff2">12.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a6cff457-6050-43d8-a4e1-7db06ac875d0"></a><a name="section-5.12"></a><p></p>
<h2>5.12 Combination With Other Drugs</h2>
<p class="First">Use of capecitabine in combination with irinotecan has not been adequately studied.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_ec51f75a-ee4b-4bb1-9683-a0cb174a42ba"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9b958de1-1821-4094-95ea-eb0f2bb36d11"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Adjuvant Colon Cancer</h2>
<p class="First"><span class="Bold"><a href="#_Ref429646243">Table 4</a></span> shows the adverse reactions occurring in ≥ 5% of patients from one phase 3 trial in patients with Dukes' C colon cancer who received at least one dose of study medication and had at least one safety assessment. A total of 995 patients were treated with 1250 mg/m<span class="Sup">2</span> twice a day of capecitabine administered for 2 weeks followed by a 1-week rest period, and 974 patients were administered 5-FU and leucovorin (20 mg/m<span class="Sup">2</span> leucovorin IV followed by 425 mg/m<span class="Sup">2</span> IV bolus 5-FU on days 1 to 5 every 28 days). The median duration of treatment was 164 days for capecitabine-treated patients and 145 days for 5-FU/LV-treated patients. A total of 112 (11%) and 73 (7%) capecitabine and 5-FU/LV-treated patients, respectively, discontinued treatment because of adverse reactions. A total of 18 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> due to all causes occurred either on study or within 28 days of receiving study drug: 8 (0.8%) patients randomized to capecitabine and 10 (1%) randomized to 5-FU/LV.</p>
<p><span class="Bold"><a href="#_Ref429646268">Table 5</a></span> shows grade 3/4 laboratory abnormalities occurring in ≥ 1% of patients from one phase 3 trial in patients with Dukes' C colon cancer who received at least one dose of study medication and had at least one safety assessment.</p>
<a name="_Ref429646243"></a><table width="100%">
<caption><span>Table 4: Percent Incidence of Adverse Reactions Reported in ≥ 5% of Patients Treated With Capecitabine or 5-FU/LV for Colon Cancer in the Adjuvant Setting (Safety Population) </span></caption>
<col width="51%">
<col width="13%">
<col width="12%">
<col width="13%">
<col width="12%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="4" valign="top"><p class="First"><span class="Bold">Adjuvant Treatment for Colon Cancer (N = 1969)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Capecitabine</span><br><span class="Bold"> (N = 995)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">5-FU/LV</span><br><span class="Bold"> (N = 974)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Body System/</span><br><span class="Bold">  Adverse Event</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">All Grades</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">Grade 3/4</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">All Grades</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Grade 3/4</span></p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">47</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">12</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">65</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">14</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">34</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">47</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">2</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">22</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">60</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">14</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">15</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">21</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">2</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">14</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">16</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">2</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">9</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">-</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">11</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Upper Abdominal Pain</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Skin and Subcutaneous Tissue Disorders</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  Hand-and-Foot Syndrome</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">60</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">17</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">9</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">-</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">22</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">-</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">8</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">General Disorders and Administration Site Conditions</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">16</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">16</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">9</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">10</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">10</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">10</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">-</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Dysgeusia</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Metabolism and Nutrition Disorders</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">9</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span></span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Blood and Lymphatic System Disorders</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">5</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Respiratory Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-</p></td>
</tr>
</tbody>
</table>
<a name="_Ref429646268"></a><table width="100%">
<caption><span>Table 5: Percent Incidence of Grade 3/4 Laboratory Abnormalities Reported in ≥ 1% of Patients Receiving Capecitabine Monotherapy for Adjuvant Treatment of Colon Cancer (Safety Population) </span></caption>
<col width="52%">
<col width="24%">
<col width="24%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="8" valign="top">
<span class="Sup">1</span>  The incidence of grade 3/4 <span class="product-label-link" type="condition" conceptid="434008" conceptname="White blood cell disorder">white blood cell abnormalities</span> was 1.3% in the capecitabine arm and 4.9% in the IV 5-FU/LV arm.<br><span class="Sup">2</span>  It should be noted that grading was according to NCIC CTC Version 1 (May, 1994). In the NCIC-CTC Version 1, <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> grade 3 indicates a bilirubin value of 1.5 to 3 × upper limit of normal (ULN) range, and grade 4 a value of &gt; 3 × ULN. The NCI CTC Version 2 and above define a grade 3 bilirubin value of &gt; 3 to 10 × ULN, and grade 4 values &gt; 10 × ULN.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"><p class="First"><span class="Bold">Adverse Event</span></p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Capecitabine</span><br><span class="Bold"> (n = 995)</span><br><span class="Bold"> Grade 3/4 %</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">IV 5-FU/LV</span><br><span class="Bold">(n = 974)</span><br><span class="Bold"> Grade 3/4 %</span></p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">Increased ALAT (SGPT)</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1.6</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">0.6</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">Increased calcium</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1.1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">0.7</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">Decreased calcium</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2.3</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">2.2</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">Decreased hemoglobin</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">1.2</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">Decreased <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">13</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">13</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">Decreased <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span><span class="Italics"><span class="Sup">1</span></span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2.2</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">26.2</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">Decreased <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span>/granulocytes</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2.4</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">26.4</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">Decreased platelets</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">0.7</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First">Increased bilirubin<span class="Italics"><span class="Sup">2</span></span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">20</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">6.3</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ec7d6276-983c-4d26-9a79-beb5ee426ff1"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Metastatic Colorectal Cancer</h2>
<p class="First"><span class="Underline">Monotherapy</span></p>
<p><span class="Bold"><a href="#_Ref429646292">Table 6</a></span> shows the adverse reactions occurring in ≥ 5% of patients from pooling the two phase 3 trials in first line metastatic colorectal cancer. A total of 596 patients with metastatic colorectal cancer were treated with 1250 mg/m<span class="Sup">2</span> twice a day of capecitabine administered for 2 weeks followed by a 1-week rest period, and 593 patients were administered 5-FU and leucovorin in the Mayo regimen (20 mg/m<span class="Sup">2</span> leucovorin IV followed by 425 mg/m<span class="Sup">2</span> IV bolus 5-FU, on days 1 to 5, every 28 days). In the pooled colorectal database the median duration of treatment was 139 days for capecitabine-treated patients and 140 days for 5-FU/LV-treated patients. A total of 78 (13%) and 63 (11%) capecitabine and 5-FU/LV-treated patients, respectively, discontinued treatment because of adverse reactions/intercurrent illness. A total of 82 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> due to all causes occurred either on study or within 28 days of receiving study drug: 50 (8.4%) patients randomized to capecitabine and 32 (5.4%) randomized to 5-FU/LV.</p>
<a name="_Ref429646292"></a><table width="100%">
<caption><span>Table 6: Pooled Phase 3 Colorectal Trials: Percent Incidence of Adverse Reactions in ≥ 5% of Patients </span></caption>
<col width="39%">
<col width="9%">
<col width="11%">
<col width="11%">
<col width="9%">
<col width="11%">
<col width="11%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="7" valign="top">– Not observed<br><span class="Sup">1</span>  Excluding <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span><br>NA = Not Applicable</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"><p class="First"><span class="Bold">Adverse Event</span></p></td>
<td class="Botrule Lrule Toprule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">Capecitabine</span><br><span class="Bold"> (n = 596)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">5-FU/LV</span><br><span class="Bold"> (n = 593)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">Total %</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">Grade 3 %</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">Grade 4 %</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">Total %</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">Grade 3 %</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Grade 4 %</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Number of Patients With &gt; One Adverse Event</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">96</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">52</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">9</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">94</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">45</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">9</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Body System/Adverse Event</span></p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">GI</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">55</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">13</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">61</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">10</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">2</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">43</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">51</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">27</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">30</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">25</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">62</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">14</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">35</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">9</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">31</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4096856" conceptname="Incomplete passage of stool">Gastrointestinal Motility Disorder</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">10</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">14</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">17</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4150136" conceptname="Discomfort in mouth">Oral Discomfort</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">10</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">10</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  Upper GI Inflammatory Disorders</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">8</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">10</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal Hemorrhage</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Ileus</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Skin and Subcutaneous</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  Hand-and-Foot Syndrome</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">54</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">17</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">NA</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">NA</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Dermatitis</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">27</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">26</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">Skin Discoloration</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">21</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">General</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>/<span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">42</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">46</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">18</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">21</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">15</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">9</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">12</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">10</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Neurological</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4318869" conceptname="Sensory neuropathy">Peripheral Sensory Neuropathy</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">10</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">10</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span><span class="Italics"><span class="Sup">1</span></span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">8</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">8</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste Disturbance</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">11</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Metabolism</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Appetite Decreased</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">26</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">31</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">8</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Eye</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">Eye Irritation</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">13</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">10</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4265433" conceptname="Visual impairment">Vision Abnormal</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Respiratory</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">14</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">10</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">8</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="31057" conceptname="Disorder of pharynx">Pharyngeal Disorder</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">Sore Throat</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Musculoskeletal</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">10</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">9</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">8</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Vascular</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">Venous Thrombosis</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">8</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Psychiatric</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  Mood Alteration</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule Toprule" valign="top"><p class="First"><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></span></p></td>
<td class="Botrule Lrule Toprule" valign="top"></td>
<td class="Botrule Lrule Toprule" valign="top"></td>
<td class="Botrule Lrule Toprule" valign="top"></td>
<td class="Botrule Lrule Toprule" valign="top"></td>
<td class="Botrule Lrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Toprule" valign="top"><p class="First">  Viral</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Blood and Lymphatic</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">80</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">79</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">13</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">46</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">13</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Hepatobiliary</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">48</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">18</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">17</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f2bd060f-059f-4523-83bf-3916ff60b216"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Breast Cancer </h2>
<p class="First"><span class="Underline">In Combination with Docetaxel</span></p>
<p>The following data are shown for the combination study with capecitabine and docetaxel in patients with metastatic breast cancer in <span class="Bold"><a href="#_Ref429646308">Table 7</a></span> and <span class="Bold"><a href="#_Ref429646323">Table 8</a></span>. In the capecitabine and docetaxel combination arm the treatment was capecitabine administered orally 1250 mg/m<span class="Sup">2</span> twice daily as intermittent therapy (2 weeks of treatment followed by 1 week without treatment) for at least 6 weeks and docetaxel administered as a 1-hour intravenous infusion at a dose of 75 mg/m<span class="Sup">2</span> on the first day of each 3-week cycle for at least 6 weeks. In the monotherapy arm docetaxel was administered as a 1-hour intravenous infusion at a dose of 100 mg/m<span class="Sup">2</span> on the first day of each 3-week cycle for at least 6 weeks. The mean duration of treatment was 129 days in the combination arm and 98 days in the monotherapy arm. A total of 66 patients (26%) in the combination arm and 49 (19%) in the monotherapy arm withdrew from the study because of adverse reactions. The percentage of patients requiring dose reductions due to adverse reactions was 65% in the combination arm and 36% in the monotherapy arm. The percentage of patients requiring treatment interruptions due to adverse reactions in the combination arm was 79%. Treatment interruptions were part of the dose modification scheme for the combination therapy arm but not for the docetaxel monotherapy-treated patients.</p>
<a name="_Ref429646308"></a><table width="100%">
<caption><span>Table 7: Percent Incidence of Adverse Events Considered Related or Unrelated to Treatment in ≥ 5% of Patients Participating in the Capecitabine and Docetaxel Combination vs Docetaxel Monotherapy Study </span></caption>
<col width="41%">
<col width="8%">
<col width="11%">
<col width="11%">
<col width="8%">
<col width="11%">
<col width="11%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="7" valign="top">– Not observed<br>NA = Not Applicable</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"><p class="First"><span class="Bold">Adverse Event</span></p></td>
<td class="Botrule Lrule Toprule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">Capecitabine 1250 mg/m<span class="Sup">2</span>/bid</span><br><span class="Bold"> With Docetaxel</span><br><span class="Bold">75 mg/m<span class="Sup">2</span>/3 weeks</span><br><span class="Bold">(n = 251)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">Docetaxel</span><br><span class="Bold"> 100 mg/m<span class="Sup">2</span>/3 weeks</span><br><span class="Bold">(n = 255)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">Total %</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">Grade 3 %</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">Grade 4 %</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">Total %</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">Grade 3 %</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Grade 4 %</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Number of Patients With at Least One Adverse Event</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">99</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">76.5</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">29.1</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">97</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">57.6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">31.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Body System/Adverse Event</span></p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">GI </span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">67</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">14</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">48</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">67</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">17</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">43</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">45</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">36</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">35</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">24</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">20</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">18</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">30</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 3</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">24</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">14</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">8</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Skin and Subcutaneous</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  Hand-and-Foot Syndrome</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">63</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">24</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">NA</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">8</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">NA</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">41</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">42</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">Nail Disorder</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">14</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">15</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Dermatitis</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">8</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">11</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> Erythematous</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">9</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4006158" conceptname="Leukonychia">Nail Discoloration</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4328079" conceptname="Onycholysis">Onycholysis</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">General</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">28</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">34</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">26</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">25</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">22</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">27</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">16</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">11</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in Limb</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">13</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">13</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span> (non-cardiac)</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span>-like Illness</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Neurological</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste Disturbance</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">16</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">14</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">15</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">15</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">12</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">16</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">12</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">8</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">8</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">10</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">10</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypoaesthesia</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">8</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Metabolism</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">13</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">11</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Appetite Decreased</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">10</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight Decreased</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">10</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Eye</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">Lacrimation Increased</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">12</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">Eye Irritation</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Musculoskeletal</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">15</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">24</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">15</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">25</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">12</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">11</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">Bone Pain</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">8</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">10</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Cardiac</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">33</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">&lt; 2</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">34</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">&lt; 3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Blood</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Neutropenic Fever</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">16</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">13</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">21</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">16</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Respiratory</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">14</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">16</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">13</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">22</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">Sore Throat</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">12</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">11</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">Rhinorrhea</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">Pleural Effusion</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">Oral Candidiasis</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">8</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  Upper Respiratory Tract</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Vascular</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="435839" conceptname="Lymphedema">Lymphoedema</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Psychiatric</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
</tbody>
</table>
<a name="_Ref429646323"></a><table width="100%">
<caption><span>Table 8: Percent of Patients With Laboratory Abnormalities Participating in the Capecitabine and Docetaxel Combination vs Docetaxel Monotherapy Study </span></caption>
<col width="32%">
<col width="10%">
<col width="12%">
<col width="12%">
<col width="10%">
<col width="12%">
<col width="12%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"><p class="First"><span class="Bold">Adverse Event</span></p></td>
<td class="Botrule Lrule Toprule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">Capecitabine 1250 mg/m<span class="Sup">2</span>/bid</span><br><span class="Bold"> With Docetaxel</span><br><span class="Bold">75 mg/m<span class="Sup">2</span>/3 weeks</span><br><span class="Bold"> (n = 251)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">Docetaxel</span><br><span class="Bold">100 mg/m<span class="Sup">2</span>/3 weeks</span><br><span class="Bold">(n = 255)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Body System/Adverse Event </span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">Total %</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">Grade 3 %</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">Grade 4 %</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">Total %</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">Grade 3 %</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Grade 4 %</span></p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Hematologic</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">91</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">37</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">24</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">88</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">42</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">33</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>/<span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">Granulocytopenia</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">86</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">20</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">49</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">87</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">10</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">66</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">41</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">23</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">2</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">80</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">83</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">Lymphocytopenia</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">99</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">48</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">41</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">98</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">44</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">40</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Hepatobiliary</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">20</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2</p></td>
</tr>
</tbody>
</table>
<p><span class="Underline">Monotherapy</span></p>
<p>The following data are shown for the study in stage IV breast cancer patients who received a dose of 1250 mg/m<span class="Sup">2</span> administered twice daily for 2 weeks followed by a 1-week rest period. The mean duration of treatment was 114 days. A total of 13 out of 162 patients (8%) discontinued treatment because of adverse reactions/intercurrent illness.</p>
<a name="_RefID88D0A7F6533E4E4DBC4079F4052A4DB3"></a><table width="100%">
<caption><span>Table 9: Percent Incidence of Adverse Reactions Considered Remotely, Possibly or Probably Related to Treatment in ≥ 5% of Patients Participating in the Single Arm Trial in Stage IV Breast Cancer </span></caption>
<col width="42%">
<col width="17%">
<col width="21%">
<col width="21%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="18" valign="top">– Not observed<br>NA = Not Applicable</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"><p class="First"><span class="Bold">Adverse Event</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">Phase 2 Trial in Stage IV Breast Cancer</span><br><span class="Bold">(n = 162)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Body System/Adverse Event</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">Total %</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">Grade 3 %</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Grade 4 %</span></p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">GI</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">57</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">12</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">3</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">53</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">37</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">24</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">20</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">15</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">8</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Skin and Subcutaneous</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">Hand-and-Foot Syndrome</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">57</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">11</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">NA</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Dermatitis</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">37</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">Nail Disorder</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">General</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">41</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">8</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">12</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in Limb</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Neurological</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">21</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">9</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">8</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">8</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Metabolism</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">23</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Eye</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">Eye Irritation</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">15</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Musculoskeletal</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">9</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">–</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Cardiac</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">9</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">–</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Blood</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">26</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">2</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">24</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">72</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">Lymphopenia</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">94</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">44</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">15</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Hepatobiliary</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">22</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d2239c42-247d-4a23-a25b-0d3732a51e27"></a><a name="section-6.4"></a><p></p>
<h2>6.4 Clinically Relevant Adverse Events in &lt; 5% of Patients</h2>
<p class="First">Clinically relevant adverse events reported in &lt; 5% of patients treated with capecitabine either as monotherapy or in combination with docetaxel that were considered at least remotely related to treatment are shown below; occurrences of each grade 3 and 4 adverse event are provided in parentheses.</p>
<p><span class="Underline">Monotherapy (Metastatic Colorectal Cancer, Adjuvant Colorectal Cancer, Metastatic Breast Cancer)</span></p>
<table width="100%">
<col width="23%">
<col width="77%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"><p class="First"><span class="Italics">Gastrointestinal:</span></p></td>
<td class="Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdominal distension</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="76458" conceptname="Rectal pain">proctalgia</span>, <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span> (0.1%), <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span> (0.1%), <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span> (0.3%), toxic dilation of intestine, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span> (0.1%)</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Italics">Skin &amp; Subcutan.:</span></p></td>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">nail disorder</span> (0.1%), <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating increased</span> (0.1%), <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span> (0.1%), <span class="product-label-link" type="condition" conceptid="4262920" conceptname="Skin ulcer">skin ulceration</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4033685" conceptname="Radiation recall syndrome">radiation recall syndrome</span> (0.2%)</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Italics">General:</span></p></td>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> (0.2%), <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like illness, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (0.1%), <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">hoarseness</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">difficulty in walking</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, chest <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span>, collapse, <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> (0.1%), <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, sedation</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Italics">Neurological:</span></p></td>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span> (0.5%), <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="440424" conceptname="Aphasia">dysphasia</span>, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> (0.1%), abnormal coordination, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> (0.2%), impaired balance</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Italics">Metabolism:</span></p></td>
<td valign="top"><p class="First">increased weight, <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">cachexia</span> (0.4%), <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> (0.1%), <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span></p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Italics">Eye:</span></p></td>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span></p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Italics">Respiratory:</span></p></td>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> (0.1%), <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span> (0.1%), <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> (0.2%), <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> (0.1%), <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span></p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Italics">Cardiac:</span></p></td>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> (0.1%), <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="4008580" conceptname="Ventricular bigeminy">ventricular extrasystoles</span>, <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">extrasystoles</span>, <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span> (0.1%), <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">pericardial effusion</span></p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>:</span></p></td>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">laryngitis</span> (1%), <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span> (0.2%), <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (0.2%), <span class="product-label-link" type="condition" conceptid="256722" conceptname="Bronchopneumonia">bronchopneumonia</span> (0.2%), <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratoconjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> (0.3%), <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> (including <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span>) (0.2%)</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Italics">Musculoskeletal:</span></p></td>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span> (0.1%), <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span> (0.1%), <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span></p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Italics">Blood &amp; Lymphatic:</span></p></td>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (0.2%), <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorder</span> (0.1%), <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span> (0.1%), <span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">idiopathic thrombocytopenia</span> purpura (1%), <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> (0.1%)</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Italics">Vascular:</span></p></td>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (0.2%), <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (0.1%), <span class="product-label-link" type="condition" conceptid="435839" conceptname="Lymphedema">lymphoedema</span> (0.1%), <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (0.2%), <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span> (0.1%)</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Italics">Psychiatric:</span></p></td>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> (0.1%)</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Italics">Renal:</span></p></td>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (0.6%)</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Italics">Ear:</span></p></td>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Italics">Hepatobiliary:</span></p></td>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4267417" conceptname="Hepatic fibrosis">hepatic fibrosis</span> (0.1%), <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> (0.1%), <span class="product-label-link" type="condition" conceptid="4318541" conceptname="Cholestatic hepatitis">cholestatic hepatitis</span> (0.1%), <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span></p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Italics">Immune System:</span></p></td>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">drug hypersensitivity</span> (0.1%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First"><span class="Italics">Postmarketing: </span></p></td>
<td class="Botrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, lacrimal duct stenosis, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> secondary to <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> including fatal outcome [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_e875c4a4-1f00-4636-9d9e-67850c7d12b2">5.5</a>)</span>], <span class="product-label-link" type="condition" conceptid="4324123" conceptname="Cutaneous lupus erythematosus">cutaneous lupus erythematosus</span>, <span class="product-label-link" type="condition" conceptid="376408" conceptname="Descemetocele">corneal disorders</span> including <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> such as <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">Toxic Epidermal Necrolysis</span> (TEN) [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_e065f01f-ec6b-4c74-81e0-38a6cbb534e9">5.7</a>)</span>]</p></td>
</tr>
</tbody>
</table>
<p><span class="Underline">Capecitabine In Combination With Docetaxel (Metastatic Breast Cancer)</span></p>
<table width="100%">
<col width="22%">
<col width="78%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"><p class="First"><span class="Italics">Gastrointestinal: </span></p></td>
<td class="Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span> (0.4%), <span class="product-label-link" type="condition" conceptid="201957" conceptname="Necrotizing enterocolitis in fetus OR newborn">necrotizing enterocolitis</span> (0.4%), <span class="product-label-link" type="condition" conceptid="25844" conceptname="Ulcer of esophagus">esophageal ulcer</span> (0.4%), <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">hemorrhagic diarrhea</span> (0.8%)</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Italics">Neurological:</span></p></td>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span> (0.4%), <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> (1.2%), <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">taste loss</span> (0.8%), <span class="product-label-link" type="condition" conceptid="4174262" conceptname="Polyneuropathy">polyneuropathy</span> (0.4%), <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> (0.4%)</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Italics">Cardiac:</span></p></td>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span> (0.4%)</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>: </span></p></td>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="40484176" conceptname="Neutropenic sepsis">neutropenic sepsis</span> (2.4%), <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> (0.4%), <span class="product-label-link" type="condition" conceptid="256722" conceptname="Bronchopneumonia">bronchopneumonia</span> (0.4%)</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Italics">Blood &amp; Lymphatic:</span></p></td>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> (0.4%), <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> decreased (0.4%)</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Italics">Vascular:</span></p></td>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (1.2%), venous <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span> and <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> (0.4%), <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> (0.8%)</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Italics">Renal:</span></p></td>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> (0.4%)</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Italics">Hepatobiliary:</span></p></td>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (0.4%), <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span> (0.4%), <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> (0.4%), <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span> (0.4%), hepatotoxicity (0.4%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First"><span class="Italics">Immune System:</span></p></td>
<td class="Botrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (1.2%)</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_663f9dd4-5c87-4312-b3ae-db1680d70742"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7565bfb6-a1ff-435c-8296-5b8e8145d18b"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Drug-Drug Interactions</h2>
<p class="First"><span class="Underline">Anticoagulants</span></p>
<p>Altered coagulation parameters and/or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon [<span class="Italics">see <a href="#i4i_boxed_warning_id_d82ab764-9f72-4cc3-8bd2-f3d8cd97def7">Boxed Warning</a></span>]. These events occurred within several days and up to several months after initiating capecitabine therapy and, in a few cases, within 1 month after stopping capecitabine. These events occurred in patients with and without liver <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>. In a drug interaction study with single-dose warfarin administration, there was a significant increase in the mean AUC of S-warfarin [<span class="Italics">see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_27d04e08-8b25-4fde-9ec6-60db982c0ff2">12.3</a>)</span>]. The maximum observed INR value increased by 91%. This interaction is probably due to an inhibition of cytochrome P450 2C9 by capecitabine and/or its metabolites.</p>
<p><span class="Underline">Phenytoin</span></p>
<p>The level of phenytoin should be carefully monitored in patients taking capecitabine and phenytoin dose may need to be reduced [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_9d9aac28-13cc-4f1f-8a10-8665b23637ec">2.2</a>)</span>]. Postmarketing reports indicate that some patients receiving capecitabine and phenytoin had toxicity associated with elevated phenytoin levels. Formal drug-drug interaction studies with phenytoin have not been conducted, but the mechanism of interaction is presumed to be inhibition of the CYP2C9 isoenzyme by capecitabine and/or its metabolites.</p>
<p><span class="Underline">Leucovorin</span></p>
<p>The concentration of 5-fluorouracil is increased and its toxicity may be enhanced by leucovorin. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> from severe <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> have been reported in elderly patients receiving weekly leucovorin and fluorouracil.</p>
<p><span class="Underline">CYP2C9 substrates</span></p>
<p>Other than warfarin, no formal drug-drug interaction studies between capecitabine and other CYP2C9 substrates have been conducted. Care should be exercised when capecitabine is coadministered with CYP2C9 substrates.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_caaae313-8dd6-4fe8-8b89-cc1d4449cca7"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Drug-Food Interaction</h2>
<p class="First">Food was shown to reduce both the rate and extent of absorption of capecitabine [<span class="Italics">see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_27d04e08-8b25-4fde-9ec6-60db982c0ff2">12.3</a>)</span>]. In all clinical trials, patients were instructed to administer capecitabine within 30 minutes after a meal. It is recommended that capecitabine be administered with food [<span class="Italics">see Dosage and Administration (<a href="#i4i_dosage_admin_id_4ee8b0f1-a394-4b39-bffd-95fdf45802a8">2</a>)</span>]<span class="Italics">.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_929bb412-e3fe-47e9-b585-6ad60ba74b85"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_6c31851f-7b16-4a65-896d-d81df13fcc8c"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Italics">Teratogenic Effects</span></p>
<p><span class="Underline">Pregnancy Category D</span></p>
<p>Capecitabine can cause fetal harm when administered to a pregnant woman. Capecitabine at doses of 198 mg/kg/day during organogenesis caused malformations and embryo <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in mice. In separate pharmacokinetic studies, this dose in mice produced 5'-DFUR AUC values about 0.2 times the corresponding values in patients administered the recommended daily dose. Malformations in mice included <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>, <span class="product-label-link" type="condition" conceptid="434143" conceptname="Anophthalmos">anophthalmia</span>, <span class="product-label-link" type="condition" conceptid="376512" conceptname="Microphthalmos">microphthalmia</span>, oligodactyly, <span class="product-label-link" type="condition" conceptid="74740" conceptname="Polydactyly">polydactyly</span>, <span class="product-label-link" type="condition" conceptid="4162283" conceptname="Syndactyly">syndactyly</span>, kinky tail and dilation of cerebral ventricles. At doses of 90 mg/kg/day, capecitabine given to pregnant monkeys during organogenesis caused <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span>. This dose produced 5'-DFUR AUC values about 0.6 times the corresponding values in patients administered the recommended daily dose.</p>
<p>There are no adequate and well controlled studies of capecitabine in pregnant women. If this drug is used during pregnancy, or if a patient becomes pregnant while receiving capecitabine, the patient should be apprised of the potential hazard to the fetus. Women should be advised to avoid becoming pregnant while receiving treatment with capecitabine [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_2a5297ef-8968-495f-8a79-c46e46995e50">5.6</a>)</span>]<span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_52abbfce-c22d-49d8-985e-e9f750ca9385"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Lactating mice given a single oral dose of capecitabine excreted significant amounts of capecitabine metabolites into the milk. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from capecitabine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_9097fcbe-9c73-4356-86c4-a3cea9232bb9"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of capecitabine in pediatric patients have not been established. No clinical benefit was demonstrated in two single arm trials in pediatric patients with newly diagnosed brainstem <span class="product-label-link" type="condition" conceptid="4019491" conceptname="Glioma">gliomas</span> and high grade <span class="product-label-link" type="condition" conceptid="4019491" conceptname="Glioma">gliomas</span>. In both trials, pediatric patients received an investigational pediatric formulation of capecitabine concomitantly with and following completion of radiation therapy (total dose of 5580 cGy in 180 cGy fractions). The relative bioavailability of the investigational formulation to capecitabine was similar. </p>
<p>The first trial was conducted in 22 pediatric patients (median age 8 years, range 5 to 17 years) with newly diagnosed non-disseminated intrinsic diffuse brainstem <span class="product-label-link" type="condition" conceptid="4019491" conceptname="Glioma">gliomas</span> and high grade <span class="product-label-link" type="condition" conceptid="4019491" conceptname="Glioma">gliomas</span>. In the dose-finding portion of the trial, patients received capecitabine with concomitant radiation  therapy at doses ranging from 500 mg/m<span class="Sup">2</span> to 850 mg/m<span class="Sup">2</span> every 12 hours for up to 9 weeks. After a 2 week break, patients received 1250 mg/m<span class="Sup">2</span> capecitabine every 12 hours on Days 1 to 14 of a 21-day cycle for up to 3 cycles. The maximum tolerated dose (MTD) of capecitabine administered concomitantly with radiation therapy was 650 mg/m<span class="Sup">2</span> every 12 hours. The major dose limiting toxicities were palmar-plantar erythrodysesthesia and <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> (ALT) elevation.  </p>
<p>The second trial was conducted in 34 additional pediatric patients with newly diagnosed non-disseminated intrinsic diffuse brainstem <span class="product-label-link" type="condition" conceptid="4019491" conceptname="Glioma">gliomas</span> (median age 7 years, range 3 to 16 years) and 10 pediatric patients who received the MTD of capecitabine in the dose-finding trial and met the eligibility criteria for this trial. All patients received 650 mg/m<span class="Sup">2</span> capecitabine every 12 hours with concomitant radiation therapy for up to 9 weeks. After a 2 week break, patients received 1250 mg/m<span class="Sup">2</span> capecitabine every 12 hours on Days 1 to 14 of a 21-day cycle for up to 3 cycles.</p>
<p>There was no improvement in one-year progression-free survival rate and one-year overall survival  rate in pediatric patients with newly diagnosed intrinsic brainstem <span class="product-label-link" type="condition" conceptid="4019491" conceptname="Glioma">gliomas</span> who received  capecitabine relative to a similar population of pediatric patients who participated in other clinical  trials. </p>
<p>The adverse reaction profile of capecitabine was consistent with the known adverse reaction profile in adults, with the exception of laboratory abnormalities which occurred more commonly in pediatric patients. The most frequently reported laboratory abnormalities (per-patient incidence ≥ 40%) were increased ALT (75%), <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphocytopenia</span> (73%), <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (73%), <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> (68%),  <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (57%), <span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">hypoalbuminemia</span> (55%), <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (50%), low hematocrit (50%),  <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> (48%), <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span> (45%) and <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> (45%).</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_65c546e2-b758-44de-8240-f9dd6a917f2c"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Physicians should pay particular attention to monitoring the adverse effects of capecitabine in the elderly [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_ea741bb7-3bb6-4dc2-8b43-f05175530c4b">5.11</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_830efa38-0f3c-43d0-b537-521c325ae087"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></h2>
<p class="First">Exercise caution when patients with mild to moderate hepatic dysfunction due to liver <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> are treated with capecitabine. The effect of severe hepatic dysfunction on capecitabine is not known [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_a6cff457-6050-43d8-a4e1-7db06ac875d0">5.12</a>) </span>and<span class="Italics"> Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_27d04e08-8b25-4fde-9ec6-60db982c0ff2">12.3</a>)</span>]<span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0e30f7d8-a584-4c73-8034-19dfcf434247"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></h2>
<p class="First">Patients with moderate (creatinine clearance = 30 to 50 mL/min) and severe (creatinine clearance &lt; 30 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> showed higher exposure for capecitabine, 5-DFUR, and FBAL than in those with normal renal function [<span class="Italics">see Contraindications (<a href="#i4i_section_id_9d899da5-6f48-43c0-91ad-a7a2c387a649">4.2</a>), Warnings and Precautions (<a href="#i4i_section_id_e875c4a4-1f00-4636-9d9e-67850c7d12b2">5.5</a>), Dosage and Administration (<a href="#i4i_section_id_7a50b455-b993-4e92-b221-516c5cb5017c">2.3</a>), </span>and<span class="Italics"> Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_27d04e08-8b25-4fde-9ec6-60db982c0ff2">12.3</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_11ebe31d-7045-4b51-a51b-c1a258d2d3a1"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">The manifestations of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdose</span> would include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4318531" conceptname="Gastrointestinal irritation">gastrointestinal irritation</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>. Medical management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> should include customary supportive medical interventions aimed at correcting the presenting clinical manifestations. Although no clinical experience using dialysis as a treatment for capecitabine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> has been reported, dialysis may be of benefit in reducing circulating concentrations of 5'-DFUR, a low–molecular-weight metabolite of the parent compound.</p>
<p>Single doses of capecitabine were not lethal to mice, rats, and monkeys at doses up to 2000 mg/kg (2.4, 4.8, and 9.6 times the recommended human daily dose on a mg/m<span class="Sup">2</span> basis).</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_bfc56764-ba03-4c08-9137-d473ba6c10cf"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Capecitabine Tablets USP are a fluoropyrimidine carbamate with antineoplastic activity. They are an orally administered systemic prodrug of 5'-deoxy-5-fluorouridine (5'-DFUR) which is converted to 5-fluorouracil.</p>
<p>The chemical name for capecitabine, USP is 5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine and has the following structural formula:</p>
<div class="Figure">
<a name="id3331"></a><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2777b481-7d7f-461a-b5e0-c09ce2990c34&amp;name=image-01.jpg">
</div>
<p><span class="Bold">                                                        C<span class="Sub">15</span>H<span class="Sub">22</span>FN<span class="Sub">3</span>O<span class="Sub">6</span>                        M.W. 359.35 </span></p>
<p>Capecitabine, USP is a white to off-white crystalline powder with an aqueous solubility of 26 mg/mL at 20°C.</p>
<p>Capecitabine Tablets USP are supplied as oblong, film-coated, biconvex, unscored tablets for oral administration. Each peach to light peach-colored tablet contains 150 mg or 500 mg capecitabine, USP. The inactive ingredients are as follows: anhydrous lactose, croscarmellose sodium, hypromellose, magnesium stearate, microcrystalline cellulose, red iron oxide, talc, titanium dioxide, and yellow iron oxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_97aa6bb5-4162-451d-9a74-05478514d832"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_8ef44295-f9b0-4c4b-9dfc-5fcb7b81396a"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Enzymes convert capecitabine to 5-fluorouracil (5-FU) <span class="Italics">in vivo</span>. Both normal and tumor cells metabolize 5-FU to 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). These metabolites cause cell injury by two different mechanisms. First, FdUMP and the folate cofactor, N<span class="Sup">5-10</span>-methylenetetrahydrofolate, bind to thymidylate synthase (TS) to form a covalently bound ternary complex. This binding inhibits the formation of thymidylate from 2'-deoxyuridylate. Thymidylate is the necessary precursor of thymidine triphosphate, which is essential for the synthesis of DNA, so that a deficiency of this compound can inhibit cell division. Second, nuclear transcriptional enzymes can mistakenly incorporate FUTP in place of uridine triphosphate (UTP) during the synthesis of RNA. This metabolic error can interfere with RNA processing and protein synthesis.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_27d04e08-8b25-4fde-9ec6-60db982c0ff2"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Bold"><span class="Italics">Absorption</span></span></p>
<p>Following oral administration of 1255 mg/m<span class="Sup">2</span> BID to cancer patients, capecitabine reached peak blood levels in about 1.5 hours (T<span class="Sub">max</span>) with peak 5-FU levels occurring slightly later, at 2 hours. Food reduced both the rate and extent of absorption of capecitabine with mean C<span class="Sub">max</span> and AUC<span class="Sub">0 to ∞</span> decreased by 60% and 35%, respectively. The C<span class="Sub">max</span> and AUC<span class="Sub">0 to ∞ </span>of 5-FU were also reduced by food by 43% and 21%, respectively. Food delayed T<span class="Sub">max</span> of both parent and 5-FU by 1.5 hours [<span class="Italics">see Warnings and Precautions (<a href="#i4i_warnings_precautions_id_32de6a8d-14ca-4473-b8a5-6f08739ee537">5</a>), Dosage and Administration (<a href="#i4i_dosage_admin_id_4ee8b0f1-a394-4b39-bffd-95fdf45802a8">2</a>), </span>and<span class="Italics"> Drug-Food Interaction (<a href="#i4i_section_id_caaae313-8dd6-4fe8-8b89-cc1d4449cca7">7.2</a>)</span>].</p>
<p>The pharmacokinetics of capecitabine and its metabolites have been evaluated in about 200 cancer patients over a dosage range of 500 to 3500 mg/m<span class="Sup">2</span>/day. Over this range, the pharmacokinetics of capecitabine and its metabolite, 5'-DFCR were dose proportional and did not change over time. The increases in the AUCs of 5'-DFUR and 5-FU, however, were greater than proportional to the increase in dose and the AUC of 5-FU was 34% higher on day 14 than on day 1. The interpatient variability in the C<span class="Sub">max </span>and AUC of 5-FU was greater than 85%.</p>
<p><span class="Bold"><span class="Italics">Distribution</span></span></p>
<p>Plasma protein binding of capecitabine and its metabolites is less than 60% and is not concentration-dependent. Capecitabine was primarily bound to human albumin (approximately 35%). Capecitabine has a low potential for <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> related to plasma protein binding.</p>
<p><span class="Bold"><span class="Italics">Bioactivation and Metabolism</span></span></p>
<p>Capecitabine is extensively metabolized enzymatically to 5-FU. In the liver, a 60 kDa carboxylesterase hydrolyzes much of the compound to 5'-deoxy-5-fluorocytidine (5'-DFCR). Cytidine deaminase, an enzyme found in most tissues, including tumors, subsequently converts 5'-DFCR to 5'-DFUR. The enzyme, thymidine phosphorylase (dThdPase), then hydrolyzes 5'-DFUR to the active drug 5-FU. Many tissues throughout the body express thymidine phosphorylase. Some human carcinomas express this enzyme in higher concentrations than surrounding normal tissues. Following oral administration of capecitabine 7 days before surgery in patients with colorectal cancer, the median ratio of 5-FU concentration in colorectal tumors to adjacent tissues was 2.9 (range from 0.9 to 8). These ratios have not been evaluated in breast cancer patients or compared to 5-FU infusion.</p>
<div class="Figure">
<a name="id3377"></a><img alt="Metabolic Pathway" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2777b481-7d7f-461a-b5e0-c09ce2990c34&amp;name=image-02.jpg">
</div>
<p><span class="Bold">Metabolic Pathway of Capecitabine to 5-FU</span></p>
<p>The enzyme dihydropyrimidine dehydrogenase hydrogenates 5-FU, the product of capecitabine metabolism, to the much less toxic 5-fluoro-5, 6-dihydro-fluorouracil (FUH<span class="Sub">2</span>). Dihydropyrimidinase cleaves the pyrimidine ring to yield 5-fluoro-ureido-propionic acid (FUPA). Finally, <span class="Italics">β</span>-ureido-propionase cleaves FUPA to <span class="Italics">α</span>-fluoro-<span class="Italics">β</span>-alanine (FBAL) which is cleared in the urine.</p>
<p>In vitro enzymatic studies with human liver microsomes indicated that capecitabine and its metabolites (5'-DFUR, 5'-DFCR, 5-FU, and FBAL) did not inhibit the metabolism of test substrates by cytochrome P450 isoenzymes 1A2, 2A6, 3A4, 2C19, 2D6, and 2E1.</p>
<p><span class="Bold"><span class="Italics">Excretion</span></span></p>
<p>Capecitabine and its metabolites are predominantly excreted in urine; 95.5% of administered capecitabine dose is recovered in urine. Fecal excretion is minimal (2.6%). The major metabolite excreted in urine is FBAL which represents 57% of the administered dose. About 3% of the administered dose is excreted in urine as unchanged drug. The elimination half-life of both parent capecitabine and 5-FU was about 0.75 hour.</p>
<p><span class="Bold"><span class="Italics">Effect of Age, Gender, and Race on the Pharmacokinetics of Capecitabine</span></span></p>
<p>A population analysis of pooled data from the two large controlled studies in patients with metastatic colorectal cancer (n = 505) who were administered capecitabine at 1250 mg/m<span class="Sup">2</span> twice a day indicated that gender (202 females and 303 males) and race (455 white/Caucasian patients, 22 black patients, and 28 patients of other race) have no influence on the pharmacokinetics of 5'-DFUR, 5-FU and FBAL. Age has no significant influence on the pharmacokinetics of 5'-DFUR and 5-FU over the range of 27 to 86 years. A 20% increase in age results in a 15% increase in AUC of FBAL [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_ea741bb7-3bb6-4dc2-8b43-f05175530c4b">5.11</a>) </span>and<span class="Italics"> Dosage and Administration (<a href="#i4i_section_id_7a50b455-b993-4e92-b221-516c5cb5017c">2.3</a>)</span>].</p>
<p>Following oral administration of 825 mg/m<span class="Sup">2</span> capecitabine twice daily for 14 days, Japanese patients (n = 18) had about 36% lower C<span class="Sub">max</span> and 24% lower AUC for capecitabine than the Caucasian patients (n = 22). Japanese patients had also about 25% lower C<span class="Sub">max</span> and 34% lower AUC for FBAL than the Caucasian patients. The clinical significance of these differences is unknown. No significant differences occurred in the exposure to other metabolites (5'-DFCR, 5'-DFUR, and 5-FU).</p>
<p><span class="Bold"><span class="Italics">Effect of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></span></span></p>
<p>Capecitabine has been evaluated in 13 patients with mild to moderate hepatic dysfunction due to liver <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> defined by a composite score including bilirubin, AST/ALT and alkaline phosphatase following a single 1255 mg/m<span class="Sup">2</span> dose of capecitabine. Both AUC<span class="Sub">0 to ∞</span> and C<span class="Sub">max</span> of capecitabine increased by 60% in patients with hepatic dysfunction compared to patients with normal hepatic function (n = 14). The AUC<span class="Sub">0 to ∞</span> and C<span class="Sub">max</span> of 5-FU were not affected. In patients with mild to moderate hepatic dysfunction due to liver <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>, caution should be exercised when capecitabine is administered. The effect of severe hepatic dysfunction on capecitabine is not known [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_ea741bb7-3bb6-4dc2-8b43-f05175530c4b">5.11</a>) </span>and<span class="Italics"> Use in Specific Populations (<a href="#i4i_section_id_830efa38-0f3c-43d0-b537-521c325ae087">8.6</a>)</span>]<span class="Italics">.</span></p>
<p><span class="Bold"><span class="Italics">Effect of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></span></span></p>
<p>Following oral administration of 1250 mg/m<span class="Sup">2</span> capecitabine twice a day to cancer patients with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, patients with moderate (creatinine clearance = 30 to 50 mL/min) and severe (creatinine clearance &lt; 30 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> showed 85% and 258% higher systemic exposure to FBAL on day 1 compared to normal renal function patients (creatinine clearance &gt; 80 mL/min). Systemic exposure to 5'-DFUR was 42% and 71% greater in moderately and severely renal impaired patients, respectively, than in normal patients. Systemic exposure to capecitabine was about 25% greater in both moderately and severely renal impaired patients [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_7a50b455-b993-4e92-b221-516c5cb5017c">2.3</a>), Contraindications (<a href="#i4i_section_id_9d899da5-6f48-43c0-91ad-a7a2c387a649">4.2</a>), Warnings and Precautions (<a href="#i4i_section_id_e875c4a4-1f00-4636-9d9e-67850c7d12b2">5.5</a>), </span>and<span class="Italics"> Use in Specific Populations (<a href="#i4i_section_id_0e30f7d8-a584-4c73-8034-19dfcf434247">8.7</a>)</span>].</p>
<p><span class="Bold"><span class="Italics">Effect of Capecitabine on the Pharmacokinetics of Warfarin</span></span></p>
<p>In four patients with cancer, chronic administration of capecitabine (1250 mg/m<span class="Sup">2 </span>bid) with a single 20 mg dose of warfarin increased the mean AUC of S-warfarin by 57% and decreased its clearance by 37%. Baseline corrected AUC of INR in these 4 patients increased by 2.8-fold, and the maximum observed mean INR value was increased by 91% [<span class="Italics">see <a href="#i4i_boxed_warning_id_d82ab764-9f72-4cc3-8bd2-f3d8cd97def7">Boxed Warning</a> </span>and<span class="Italics"> Drug Interactions (<a href="#i4i_section_id_7565bfb6-a1ff-435c-8296-5b8e8145d18b">7.1</a>)</span>]<span class="Italics">.</span></p>
<p><span class="Bold"><span class="Italics">Effect of Antacids on the Pharmacokinetics of Capecitabine</span></span></p>
<p>When Maalox<span class="Sup">®</span> (20 mL), an aluminum hydroxide- and magnesium hydroxide-containing antacid, was administered immediately after capecitabine (1250 mg/m<span class="Sup">2</span>, n = 12 cancer patients), AUC and C<span class="Sub">max</span> increased by 16% and 35%, respectively, for capecitabine and by 18% and 22%, respectively, for 5'-DFCR. No effect was observed on the other three major metabolites (5'-DFUR, 5-FU, FBAL) of capecitabine.</p>
<p><span class="Bold"><span class="Italics">Effect of Capecitabine on the Pharmacokinetics of Docetaxel and Vice Versa</span></span></p>
<p>A Phase 1 study evaluated the effect of capecitabine on the pharmacokinetics of docetaxel (Taxotere<span class="Sup">®</span>) and the effect of docetaxel on the pharmacokinetics of capecitabine was conducted in 26 patients with <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span>. Capecitabine was found to have no effect on the pharmacokinetics of docetaxel (C<span class="Sub">max</span> and AUC) and docetaxel has no effect on the pharmacokinetics of capecitabine and the 5-FU precursor 5'-DFUR.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_af0e61d5-425a-444c-9d25-b806e04910f4"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_6a2742fe-fc00-487c-9b83-fff667742124"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Adequate studies investigating the carcinogenic potential of capecitabine have not been conducted. Capecitabine was not mutagenic <span class="Italics">in vitro</span> to bacteria (Ames test) or mammalian cells (Chinese hamster V79/HPRT gene mutation assay). Capecitabine was clastogenic in vitro to human peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> but not clastogenic <span class="Italics">in vivo </span>to mouse bone marrow (micronucleus test). Fluorouracil causes mutations in bacteria and yeast. Fluorouracil also causes chromosomal abnormalities in the mouse micronucleus test <span class="Italics">in vivo</span>.</p>
<p><span class="Underline">Impairment of Fertility</span></p>
<p>In studies of fertility and general reproductive performance in female mice, oral capecitabine doses of 760 mg/kg/day (about 2300 mg/m<span class="Sup">2</span>/day) disturbed estrus and consequently caused a decrease in fertility. In mice that became pregnant, no fetuses survived this dose. The disturbance in estrus was reversible. In males, this dose caused degenerative changes in the testes, including decreases in the number of spermatocytes and spermatids. In separate pharmacokinetic studies, this dose in mice produced 5'-DFUR AUC values about 0.7 times the corresponding values in patients administered the recommended daily dose.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_677a91a9-95f6-4df1-9a4c-ad95463fca55"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bfc2c4b8-0c27-4268-af43-a62e04fff1e3"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Adjuvant Colon Cancer</h2>
<p class="First">A multicenter randomized, controlled phase 3 clinical trial in patients with Dukes' C colon cancer (X-ACT) provided data concerning the use of capecitabine for the adjuvant treatment of patients with colon cancer. The primary objective of the study was to compare disease-free survival (DFS) in patients receiving capecitabine to those receiving IV 5-FU/LV alone. In this trial, 1987 patients were randomized either to treatment with capecitabine 1250 mg/m<span class="Sup">2</span> orally twice daily for 2 weeks followed by a 1-week rest period, given as 3-week cycles for a total of 8 cycles (24 weeks) or IV bolus 5-FU 425 mg/m<span class="Sup">2</span> and 20 mg/m<span class="Sup">2</span> IV leucovorin on days 1 to 5, given as 4-week cycles for a total of 6 cycles (24 weeks). Patients in the study were required to be between 18 and 75 years of age with histologically-confirmed Dukes' stage C colon cancer with at least one positive lymph node and to have undergone (within 8 weeks prior to randomization) complete resection of the primary tumor without macroscopic or microscopic evidence of remaining tumor. Patients were also required to have no prior cytotoxic chemotherapy or immunotherapy (except steroids), and have an ECOG performance status of 0 or 1 (KPS ≥ 70%), ANC ≥ 1.5×10<span class="Sup">9</span>/L, platelets ≥ 100×10<span class="Sup">9</span>/L, serum creatinine ≤ 1.5 ULN, total bilirubin ≤ 1.5 ULN, AST/ALT ≤ 2.5 ULN and CEA within normal limits at time of randomization.</p>
<p>The baseline demographics for capecitabine and 5-FU/LV patients are shown in <span class="Bold"><a href="#_Ref429646437">Table 10</a></span>. The baseline characteristics were well-balanced between arms.</p>
<a name="_Ref429646437"></a><table width="100%">
<caption><span>Table 10: Baseline Demographics </span></caption>
<col width="50%">
<col width="29%">
<col width="21%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Capecitabine</span><br><span class="Bold">(n = 1004)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">5-FU/LV</span><br><span class="Bold">(n = 983)</span></p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">Age (median, years)</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">62</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">63</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Range</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">(25 to 80)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">(22 to 82)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">Gender</p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">   Male (n, %)</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">542 (54)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">532 (54)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">   Female (n, %)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">461 (46)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">451 (46)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">ECOG PS</p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">   0 (n, %)</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">849 (85)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">830 (85)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">   1 (n, %)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">152 (15)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">147 (15)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">Staging – Primary Tumor</p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">   PT1 (n, %)</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">12 (1)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">6 (0.6)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">   PT2 (n, %)</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">90 (9)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">92 (9)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">   PT3 (n, %)</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">763 (76)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">746 (76)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">   PT4 (n, %)</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">138 (14)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">139 (14)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">   Other (n, %)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1 (0.1)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0 (0)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">Staging – Lymph Node</p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">   pN1 (n, %)</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">695 (69)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">694 (71)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">   pN2 (n, %)</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">305 (30)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">288 (29)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First">   Other (n, %)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">4 (0.4)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1 (0.1)</p></td>
</tr>
</tbody>
</table>
<p><br>All patients with normal renal function or mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> began treatment at the full starting dose of 1250 mg/m<span class="Sup">2</span> orally twice daily. The starting dose was reduced in patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (calculated creatinine clearance 30 to 50 mL/min) at baseline [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_7a50b455-b993-4e92-b221-516c5cb5017c">2.3</a>)</span>]. Subsequently, for all patients, doses were adjusted when needed according to toxicity. Dose management for capecitabine included dose reductions, cycle delays and treatment interruptions (see <span class="Bold"><a href="#_Ref429646452">Table 11</a></span>).</p>
<a name="_Ref429646452"></a><table width="100%">
<caption><span>Table 11: Summary of Dose Modifications in X-ACT Study </span></caption>
<col width="72%">
<col width="16%">
<col width="12%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Capecitabine</span><br><span class="Bold">N = 995</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">5-FU/LV</span><br><span class="Bold">N = 974</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Median relative dose intensity (%)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">93</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">92</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Patients completing full course of treatment (%)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">83</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">87</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Patients with treatment interruption (%)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Patients with cycle delay (%)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">46</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">29</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Patients with dose reduction (%)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">42</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">44</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First">Patients with treatment interruption, cycle delay, or dose reduction (%)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">57</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">52</p></td>
</tr>
</tbody>
</table>
<p><br>The median follow-up at the time of the analysis was 83 months (6.9 years). The hazard ratio for DFS for capecitabine compared to 5-FU/LV was 0.88 (95% C.I. 0.77 to 1.01) (see <span class="Bold"><a href="#_Ref429646474">Table 12</a></span> and <span class="Bold"><a href="#id3661">Figure 1</a></span>). Because the upper 2-sided 95% confidence limit of hazard ratio was less than 1.20, capecitabine was non-inferior to 5-FU/LV. The choice of the non-inferiority margin of 1.20 corresponds to the retention of approximately 75% of the 5-FU/LV effect on DFS. The hazard ratio for capecitabine compared to 5-FU/LV with respect to overall survival was 0.86 (95% C.I. 0.74 to 1.01). The 5-year overall survival rates were 71.4% for capecitabine and 68.4% for 5-FU/LV (see <span class="Bold"><a href="#id3666">Figure 2</a></span>).</p>
<a name="_Ref429646474"></a><table width="100%">
<caption><span>Table 12: Efficacy of Capecitabine vs 5-FU/LV in Adjuvant Treatment of Colon Cancer<span class="Sup">1</span></span></caption>
<col width="61%">
<col width="23%">
<col width="16%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="9" valign="top">
<span class="Sup">1</span>  Approximately 93.4% had 5-year DFS information<br><span class="Sup">2</span>  Based on Kaplan-Meier estimates<br><span class="Sup">3</span>  Test of superiority of capecitabine vs 5-FU/LV (Wald chi-square test)</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"><p class="First"><span class="Bold"><span class="Italics">All Randomized Population</span></span></p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Capecitabine </span><br><span class="Bold">(n = 1004)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">5-FU/LV</span><br><span class="Bold">(n = 983)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Median follow-up (months)</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">83</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">83</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">5-year Disease-free Survival Rates (%)</span><span class="Italics"><span class="Sup">2</span></span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">59.1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">54.6</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">Hazard Ratio</p></td>
<td class="Lrule Rrule" align="center" colspan="2" valign="top"><p class="First">0.88</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">(Capecitabine/5-FU/LV)</p></td>
<td class="Lrule Rrule" align="center" colspan="2" valign="top"><p class="First">(0.77 to 1.01)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">(95% C.I. for Hazard Ratio)</p></td>
<td class="Lrule Rrule" colspan="2" valign="top"><p class="First"> </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First">p-value<span class="Italics"><span class="Sup">3</span></span></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><p class="First">p = 0.068</p></td>
</tr>
</tbody>
</table>
<div class="Figure">
<a name="id3661"></a><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2777b481-7d7f-461a-b5e0-c09ce2990c34&amp;name=image-03.jpg"><p class="MultiMediaCaption">Figure 1: Kaplan-Meier Estimates of Disease-Free Survival (All Randomized Population)<span class="Sup">a</span></p>
</div>
<p><span class="Bold"><span class="Sup">a</span>  Capecitabine has been demonstrated to be non-inferior to 5-FU/LV.</span></p>
<div class="Figure">
<a name="id3666"></a><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2777b481-7d7f-461a-b5e0-c09ce2990c34&amp;name=image-04.jpg"><p class="MultiMediaCaption">Figure 2: Kaplan-Meier Estimates of Overall Survival (All Randomized Population)</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_df9a9f52-e6e1-4098-ae5e-3b7042f37435"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Metastatic Colorectal Cancer</h2>
<p class="First"><span class="Underline">General</span></p>
<p>The recommended dose of capecitabine was determined in an open-label, randomized clinical study, exploring the efficacy and safety of continuous therapy with capecitabine (1331 mg/m<span class="Sup">2</span>/day in two divided doses, n = 39), intermittent therapy with capecitabine (2510 mg/m<span class="Sup">2</span>/day in two divided doses, n = 34), and intermittent therapy with capecitabine in combination with oral leucovorin (LV) (capecitabine 1657 mg/m<span class="Sup">2</span>/day in two divided doses, n = 35; leucovorin 60 mg/day) in patients with advanced and/or metastatic colorectal carcinoma in the first-line metastatic setting. There was no apparent advantage in response rate to adding leucovorin to capecitabine; however, toxicity was increased. Capecitabine, 1250 mg/m<span class="Sup">2</span> twice daily for 14 days followed by a 1-week rest, was selected for further clinical development based on the overall safety and efficacy profile of the three schedules studied.</p>
<p><span class="Underline">Monotherapy</span></p>
<p>Data from two open-label, multicenter, randomized, controlled clinical trials involving 1207 patients support the use of capecitabine in the first-line treatment of patients with metastatic colorectal carcinoma. The two clinical studies were identical in design and were conducted in 120 centers in different countries. Study 1 was conducted in the U.S., Canada, Mexico, and Brazil; Study 2 was conducted in Europe, Israel, Australia, New Zealand, and Taiwan. Altogether, in both trials, 603 patients were randomized to treatment with capecitabine at a dose of 1250 mg/m<span class="Sup">2</span> twice daily for 2 weeks followed by a 1-week rest period and given as 3-week cycles; 604 patients were randomized to treatment with 5-FU and leucovorin (20 mg/m<span class="Sup">2</span> leucovorin IV followed by 425 mg/m<span class="Sup">2</span> IV bolus 5-FU, on days 1 to 5, every 28 days).</p>
<p>In both trials, overall survival, time to progression and response rate (complete plus partial responses) were assessed. Responses were defined by the World Health Organization criteria and submitted to a blinded independent review committee (IRC). Differences in assessments between the investigator and IRC were reconciled by the sponsor, blinded to treatment arm, according to a specified algorithm. Survival was assessed based on a non-inferiority analysis.</p>
<p>The baseline demographics for capecitabine and 5-FU/LV patients are shown in <span class="Bold"><a href="#_Ref429646751">Table 13</a></span>.</p>
<a name="_Ref429646751"></a><table width="100%">
<caption><span>Table 13: Baseline Demographics of Controlled Colorectal Trials </span></caption>
<col width="32%">
<col width="18%">
<col width="16%">
<col width="18%">
<col width="16%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"></td>
<td class="Botrule Lrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Study 1</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Study 2</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">Capecitabine</span><br><span class="Bold">(n = 302)</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">5-FU/LV</span><br><span class="Bold">(n = 303)</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">Capecitabine</span><br><span class="Bold">(n = 301)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">5-FU/LV</span><br><span class="Bold">(n = 301)</span></p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">Age (median, years)</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">64</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">63</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">64</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">64</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Range</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">(23 to 86)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">(24 to 87)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">(29 to 84)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">(36 to 86)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">Gender</p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">   Male (%)</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">181 (60)</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">197 (65)</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">172 (57)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">173 (57)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">   Female (%)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">121 (40)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">106 (35)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">129 (43)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">128 (43)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">Karnofsky PS (median)</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">90</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">90</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">90</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">90</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Range</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">(70 to 100)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">(70 to 100)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">(70 to 100)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">(70 to 100)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">Colon (%) </p></td>
<td class="Lrule" align="center" valign="top"><p class="First">222 (74)</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">232 (77)</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">199 (66)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">196 (65)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Rectum (%)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">79 (26)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">70 (23)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">101 (34)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">105 (35)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Prior radiation therapy (%)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">52 (17)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">62 (21)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">42 (14)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">42 (14)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First">Prior adjuvant 5-FU (%)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">84 (28)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">110 (36)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">56 (19)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">41 (14)</p></td>
</tr>
</tbody>
</table>
<p><br>The efficacy endpoints for the two phase 3 trials are shown in <span class="Bold"><a href="#_Ref429646774">Table 14</a></span> and <span class="Bold"><a href="#_Ref429646790">Table 15</a></span>.</p>
<a name="_Ref429646774"></a><table width="100%">
<caption><span>Table 14: Efficacy of Capecitabine vs 5-FU/LV in Colorectal Cancer (Study 1) </span></caption>
<col width="51%">
<col width="24%">
<col width="24%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Capecitabine</span><br><span class="Bold">(n = 302)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">5-FU/LV</span><br><span class="Bold">(n = 303)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Overall Response Rate</span><br>(%, 95% C.I.)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">21 (16 to 26)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">11 (8 to 15)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">(<span class="Italics">p</span>-value)</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><p class="First">0.0014</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Time to Progression</span><br>(Median, days, 95% C.I.)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">128 (120 to 136)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">131 (105 to 153)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">Hazard Ratio (Capecitabine/5-FU/LV)</p></td>
<td class="Lrule Rrule" align="center" colspan="2" valign="top"><p class="First">0.99</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">95% C.I. for Hazard Ratio</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><p class="First">(0.84 to 1.17)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Survival</span><br>(Median, days, 95% C.I.)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"> <br>380 (321 to 434)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"> <br>407 (366 to 446)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">Hazard Ratio (Capecitabine/5-FU/LV)</p></td>
<td class="Lrule Rrule" align="center" colspan="2" valign="top"><p class="First">1</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First">95% C.I. for Hazard Ratio</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><p class="First">(0.84 to 1.18)</p></td>
</tr>
</tbody>
</table>
<a name="_Ref429646790"></a><table width="100%">
<caption><span>Table 15: Efficacy of Capecitabine vs 5-FU/LV in Colorectal Cancer (Study 2) </span></caption>
<col width="51%">
<col width="24%">
<col width="24%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Capecitabine</span><br><span class="Bold">(n = 301)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">5-FU/LV</span><br><span class="Bold">(n = 301)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Overall Response Rate</span><br>(%, 95% C.I.)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">21 (16 to 26)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">14 (10 to 18)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">(<span class="Italics">p</span>-value)</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><p class="First">0.027</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Time to Progression</span><br>(Median, days, 95% C.I.)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">137 (128 to 165)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">131 (102 to 156)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">Hazard Ratio (Capecitabine/5-FU/LV)</p></td>
<td class="Lrule Rrule" align="center" colspan="2" valign="top"><p class="First">0.97</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">95% C.I. for Hazard Ratio</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><p class="First">(0.82 to 1.14)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Survival</span><br>(Median, days, 95% C.I.)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"> <br>404 (367 to 452)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"> <br>369 (338 to 430)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">Hazard Ratio (Capecitabine/5-FU/LV)</p></td>
<td class="Lrule Rrule" align="center" colspan="2" valign="top"><p class="First">0.92</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First">95% C.I. for Hazard Ratio</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><p class="First">(0.78 to 1.09)</p></td>
</tr>
</tbody>
</table>
<div class="Figure">
<a name="id1491413860"></a><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2777b481-7d7f-461a-b5e0-c09ce2990c34&amp;name=image-05.jpg"><p class="MultiMediaCaption">Figure 3: Kaplan-Meier Curve for Overall Survival of Pooled Data (Studies 1 and 2)</p>
</div>
<p>Capecitabine was superior to 5-FU/LV for objective response rate in Study 1 and Study 2. The similarity of capecitabine and 5-FU/LV in these studies was assessed by examining the potential difference between the two treatments. In order to assure that capecitabine has a clinically meaningful survival effect, statistical analyses were performed to determine the percent of the survival effect of 5-FU/LV that was retained by capecitabine. The estimate of the survival effect of 5-FU/LV was derived from a meta-analysis of ten randomized studies from the published literature comparing 5-FU to regimens of 5-FU/LV that were similar to the control arms used in these Studies 1 and 2. The method for comparing the treatments was to examine the worst case (95% confidence upper bound) for the difference between 5-FU/LV and capecitabine, and to show that loss of more than 50% of the 5-FU/LV survival effect was ruled out. It was demonstrated that the percent of the survival effect of 5-FU/LV maintained was at least 61% for Study 2 and 10% for Study 1. The pooled result is consistent with a retention of at least 50% of the effect of 5-FU/LV. It should be noted that these values for preserved effect are based on the upper bound of the 5-FU/LV vs capecitabine difference. These results do not exclude the possibility of true equivalence of capecitabine to 5-FU/LV (see <span class="Bold"><a href="#_Ref429646774">Table 14</a></span>, <span class="Bold"><a href="#_Ref429646790">Table 15</a></span>, and<span class="Bold"> <a href="#id1491413860">Figure 3</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fe186317-9a05-479a-b759-451ddf6e7083"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Breast Cancer </h2>
<p class="First">Capecitabine has been evaluated in clinical trials in combination with docetaxel (Taxotere<span class="Sup">®</span>) and as monotherapy.</p>
<p><span class="Underline">In Combination With Docetaxel</span></p>
<p>The dose of capecitabine used in the phase 3 clinical trial in combination with docetaxel was based on the results of a phase 1 study, where a range of doses of docetaxel administered in 3-week cycles in combination with an intermittent regimen of capecitabine (14 days of treatment, followed by a 7-day rest period) were evaluated. The combination dose regimen was selected based on the tolerability profile of the 75 mg/m<span class="Sup">2</span> administered in 3-week cycles of docetaxel in combination with 1250 mg/m<span class="Sup">2</span> twice daily for 14 days of capecitabine administered in 3-week cycles. The approved dose of 100 mg/m<span class="Sup">2</span> of docetaxel administered in 3-week cycles was the control arm of the phase 3 study.</p>
<p>Capecitabine in combination with docetaxel was assessed in an open-label, multicenter, randomized trial in 75 centers in Europe, North America, South America, Asia, and Australia. A total of 511 patients with metastatic breast cancer resistant to, or recurring during or after an anthracycline-containing therapy, or relapsing during or recurring within 2 years of completing an anthracycline-containing adjuvant therapy were enrolled. Two hundred and fifty-five (255) patients were randomized to receive capecitabine 1250 mg/m<span class="Sup">2</span> twice daily for 14 days followed by 1 week without treatment and docetaxel 75 mg/m<span class="Sup">2</span> as a 1-hour intravenous infusion administered in 3-week cycles. In the monotherapy arm, 256 patients received docetaxel 100 mg/m<span class="Sup">2</span> as a 1-hour intravenous infusion administered in 3-week cycles. Patient demographics are provided in <span class="Bold"><a href="#_Ref429646873">Table 16</a></span>.</p>
<a name="_Ref429646873"></a><table width="100%">
<caption><span>Table 16: Baseline Demographics and Clinical Characteristics Capecitabine and Docetaxel Combination vs Docetaxel in Breast Cancer Trial </span></caption>
<col width="69%">
<col width="19%">
<col width="12%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="3" valign="top">
<span class="Sup">1</span>  Includes 10 patients in combination and 18 patients in monotherapy arms treated with an anthracenedione</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Capecitabine + Docetaxel</span><br><span class="Bold">(n = 255)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Docetaxel</span><br><span class="Bold">(n = 256)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Age </span></span>(median, years)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">52</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">51</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Karnofsky PS </span></span>(median)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">90</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">90</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Site of Disease</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  Lymph nodes</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">121 (47%)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">125 (49%)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  Liver</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">116 (45%)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">122 (48%)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  Bone</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">107 (42%)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">119 (46%)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  Lung</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">95 (37%)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">99 (39%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  Skin</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">73 (29%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">73 (29%)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Prior Chemotherapy</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  Anthracycline</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">255 (100%)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">256 (100%)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  5-FU</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">196 (77%)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">189 (74%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  Paclitaxel</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">25 (10%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">22 (9%)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Resistance to an Anthracycline</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  No resistance</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">19 (7%)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">19 (7%)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  Progression on anthracycline therapy</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">65 (26%)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">73 (29%)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">Stable disease after 4 cycles of anthracycline therapy</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">41 (16%)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">40 (16%)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">Relapsed within 2 years of completion of anthracycline-adjuvant therapy</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">78 (31%)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">74 (29%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Experienced a brief response to anthracycline   therapy, with subsequent progression while on therapy or within 12 months after last dose</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">51 (20%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50 (20%)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">No. of Prior Chemotherapy Regimens for Treatment of <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">Metastatic Disease</span></span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  0</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">89 (35%)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">80 (31%)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  1</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">123 (48%)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">135 (53%)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  2</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">43 (17%)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">39 (15%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First">  3</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0 (0%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2 (1%)</p></td>
</tr>
</tbody>
</table>
<p>Capecitabine in combination with docetaxel resulted in statistically significant improvement in time to disease progression, overall survival and objective response rate compared to monotherapy with docetaxel as shown in <span class="Bold"><a href="#_Ref429646891">Table 17</a></span>, <span class="Bold"><a href="#id-807001929">Figure 4</a></span>, and <span class="Bold"><a href="#id907115361">Figure 5</a></span>.</p>
<a name="_Ref429646891"></a><table width="100%">
<caption><span>Table 17: Efficacy of Capecitabine and Docetaxel Combination vs Docetaxel Monotherapy </span></caption>
<col width="31%">
<col width="25%">
<col width="17%">
<col width="10%">
<col width="17%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="8" valign="top">
<span class="Sup">1</span>  The response rate reported represents a reconciliation of the investigator and IRC assessments performed by the sponsor according to a predefined algorithm.<br><span class="Sup">2</span>  NA = Not Applicable</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"><p class="First"><span class="Bold">Efficacy Parameter</span></p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Combination Therapy</span></p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Monotherapy</span></p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">p-value</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Hazard Ratio</span></p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold">Time to Disease Progression</span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="Bold">Median Days</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">186</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">128</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">0.0001</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">0.643</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="Bold">95% C.I.</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">(165 to 198)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">(105 to 136)</p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold">Overall Survival</span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="Bold">Median Days</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">442</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">352</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">0.0126</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">0.775</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  <span class="Bold">95% C.I.</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">(375 to 497)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">(298 to 387)</p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"></td>
</tr>
<tr class="Last">
<td class="Lrule Toprule" valign="top"><p class="First"><span class="Bold">Response Rate</span><span class="Italics"><span class="Sup">1</span></span></p></td>
<td class="Lrule Toprule" align="center" valign="top"><p class="First">32%</p></td>
<td class="Lrule Toprule" align="center" valign="top"><p class="First">22%</p></td>
<td class="Lrule Toprule" align="center" valign="top"><p class="First">0.009</p></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"><p class="First">NA <span class="Italics"><span class="Sup">2</span></span></p></td>
</tr>
</tbody>
</table>
<div class="Figure">
<a name="id-807001929"></a><img alt="Figure 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2777b481-7d7f-461a-b5e0-c09ce2990c34&amp;name=image-06.jpg"><p class="MultiMediaCaption">Figure 4: Kaplan-Meier Estimates for Time to Disease Progression Capecitabine and Docetaxel vs Docetaxel</p>
</div>
<div class="Figure">
<a name="id907115361"></a><img alt="Figure 5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2777b481-7d7f-461a-b5e0-c09ce2990c34&amp;name=image-07.jpg"><p class="MultiMediaCaption">Figure 5: Kaplan-Meier Estimates of Survival Capecitabine and Docetaxel vs Docetaxel</p>
</div>
<p><span class="Underline">Monotherapy</span></p>
<p>The antitumor activity of capecitabine as a monotherapy was evaluated in an open-label single-arm trial conducted in 24 centers in the U.S. and Canada. A total of 162 patients with stage IV breast cancer were enrolled. The primary endpoint was tumor response rate in patients with measurable disease, with response defined as a ≥ 50% decrease in sum of the products of the perpendicular diameters of bidimensionally measurable disease for at least 1 month. Capecitabine was administered at a dose of 1255 mg/m<span class="Sup">2</span> twice daily for 2 weeks followed by a 1-week rest period and given as 3-week cycles. The baseline demographics and clinical characteristics for all patients (n = 162) and those with measurable disease (n = 135) are shown in <span class="Bold"><a href="#_Ref429646957">Table 18</a></span>. Resistance was defined as progressive disease while on treatment, with or without an initial response, or relapse within 6 months of completing treatment with an anthracycline-containing adjuvant chemotherapy regimen.</p>
<a name="_Ref429646957"></a><table width="100%">
<caption><span>Table 18: Baseline Demographics and Clinical Characteristics Single-Arm Breast Cancer Trial </span></caption>
<col width="42%">
<col width="46%">
<col width="12%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="11" valign="top">
<span class="Sup">1</span>  Lung, pleura, liver, peritoneum<br><span class="Sup">2</span>  Includes 2 patients treated with an anthracenedione</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Patients With Measurable Disease (n = 135)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"> <br><span class="Bold">All Patients</span><br><span class="Bold">(n = 162)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Age </span></span>(median, years)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">55</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">56</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Karnofsky PS</span></span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">90</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">90</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">No. Disease Sites</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  1 to 2</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">43 (32%)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">60 (37%)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  3 to 4</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">63 (46%)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">69 (43%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  &gt; 5</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">29 (22%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">34 (21%)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Dominant Site of Disease</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  Visceral<span class="Italics"><span class="Sup">1</span></span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">101 (75%)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">110 (68%)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  Soft Tissue</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">30 (22%)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">35 (22%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">  Bone</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">4 (3%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">17 (10%)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Prior Chemotherapy</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  Paclitaxel</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">135 (100%)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">162 (100%)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  Anthracycline<span class="Italics"><span class="Sup">2</span></span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">122 (90%)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">147 (91%)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">5-FU</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">110 (81%)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">133 (82%)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  Resistance to Paclitaxel</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">103 (76%)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">124 (77%)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  Resistance to an Anthracycline<span class="Italics"><span class="Sup">2</span></span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">55 (41%)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">67 (41%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First">  Resistance to both Paclitaxel and an Anthracycline<span class="Italics"><span class="Sup">2</span></span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">43 (32%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">51 (31%)</p></td>
</tr>
</tbody>
</table>
<p>Antitumor responses for patients with disease resistant to both paclitaxel and an anthracycline are shown in <span class="Bold"><a href="#_Ref429646976">Table 19</a></span>.</p>
<a name="_Ref429646976"></a><table width="100%">
<caption><span>Table 19: Response Rates in Doubly-Resistant Patients Single-Arm Breast Cancer Trial </span></caption>
<col width="32%">
<col width="68%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="13" valign="top">
<span class="Sup">1</span>  Includes 2 patients treated with an anthracenedione<br><span class="Sup">2</span>  From date of first response</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Resistance to Both Paclitaxel and an Anthracycline</span><br><span class="Bold">(n = 43)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">CR</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">PR<span class="Italics"><span class="Sup">1</span></span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">11</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">CR + PR<span class="Italics"><span class="Sup">1</span></span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">11</p></td>
</tr>
<tr>
<td class="Lrule" align="center" valign="top"><p class="First">Response Rate<span class="Italics"><span class="Sup">1</span></span></p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">25.6%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">(95% C.I.)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">(13.5, 41.2)</p></td>
</tr>
<tr>
<td class="Lrule" align="center" valign="top"><p class="First">Duration of Response,<span class="Italics"><span class="Sup">1</span></span></p></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" align="center" valign="top"><p class="First">Median in days<span class="Italics"><span class="Sup">2</span></span></p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">154</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center" valign="top"><p class="First">(Range)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">(63 to 233)</p></td>
</tr>
</tbody>
</table>
<p>For the subgroup of 43 patients who were doubly resistant, the median time to progression was 102 days and the median survival was 255 days. The objective response rate in this population was supported by a response rate of 18.5% (1 CR, 24 PRs) in the overall population of 135 patients with measurable disease, who were less resistant to chemotherapy (see <span class="Bold"><a href="#_Ref429646957">Table 18</a></span>). The median time to progression was 90 days and the median survival was 306 days.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_2f61d491-b2ab-4082-b645-11efdc91667a"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<dl>
<dt>1.</dt>
<dd>NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004-165.</dd>
<dt>2.</dt>
<dd>OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA, 1999. http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html</dd>
<dt>3.</dt>
<dd>American Society of Health-System Pharmacists. ASHP Guidelines on Handling Hazardous Drugs: <span class="Italics">Am J Health-Syst Pharm</span>. 2006;63:1172-1193.</dd>
<dt>4.</dt>
<dd>Polovich M., White JM, Kelleher LO (eds). Chemotherapy and biotherapy guidelines and recommendations for practice (2nd ed.) 2005. Pittsburgh, PA: Oncology Nursing Society.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_5989ff2e-3757-45cc-a7e7-61f498cef360"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Capecitabine Tablets USP are available as follows: </p>
<p>500 mg: Peach to light peach, oblong, film-coated, biconvex, unscored tablets debossed with 191 on one side and 77 on the other side. Available in unit dose packages of 30 (3 x 10) NDC 60687-149-21.</p>
<p><span class="Bold">Storage and Handling</span></p>
<p>Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. </p>
<p>KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.</p>
<p>Care should be exercised in the handling of capecitabine tablets USP. Capecitabine tablets USP should not be cut or crushed. Procedures for the proper handling and disposal of anticancer drugs should be considered. Any unused product should be disposed of in accordance with local requirements, or drug take back programs. Several guidelines on the subject have been published.<span class="Sup">1 to 4</span></p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_81e9638b-eff0-4131-9d36-ff0feaec5063"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Bold">Information for Patients (see FDA-approved Patient Labeling)</span></p>
<p>Patients and patients’ caregivers should be informed of the expected adverse effects of capecitabine, particularly <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and hand-and-foot syndrome, and should be made aware that patient-specific dose adaptations during therapy are expected and necessary <span class="Italics">[see Dosage and Administration (<a href="#i4i_section_id_9d9aac28-13cc-4f1f-8a10-8665b23637ec">2.2</a>)]</span>. As described below, patients taking capecitabine should be informed of the need to interrupt treatment and to call their physician immediately if moderate or severe toxicity occurs. Patients should be encouraged to recognize the common grade 2 toxicities associated with capecitabine treatment See FDA-approved patient labeling (Patient Information).</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></span></p>
<p>Patients experiencing grade 2 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (an increase of 4 to 6 stools/day or nocturnal stools) or greater or experiencing severe <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span> with severe <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> should be instructed to stop taking capecitabine and to call their physician immediately. Standard antidiarrheal treatments (e.g., loperamide) are recommended.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span> </span></p>
<p>Patients experiencing grade 2 or higher <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> should be instructed to stop taking capecitabine immediately and the <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> corrected. Treatment should not be restarted until the patient is rehydrated and any precipitating causes have been corrected or controlled.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></span></p>
<p>Patients experiencing grade 2 <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (food intake significantly decreased but able to eat intermittently) or greater should be instructed to stop taking capecitabine immediately. Initiation of symptomatic treatment is recommended.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></span></p>
<p>Patients experiencing grade 2 <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (2 to 5 episodes in a 24-hour period) or greater should be instructed to stop taking capecitabine immediately. Initiation of symptomatic treatment is recommended.</p>
<p><span class="Underline">Hand-and-Foot Syndrome</span></p>
<p>Patients experiencing grade 2 hand-and-foot syndrome (painful <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the hands and/or feet and/or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> affecting the patients’ activities of daily living) or greater should be instructed to stop taking capecitabine immediately. Initiation of symptomatic treatment is recommended.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></span></p>
<p>Patients experiencing grade 2 <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> (painful <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> or <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> of the mouth or tongue, but able to eat) or greater should be instructed to stop taking capecitabine immediately and to call their physician. Initiation of symptomatic treatment is recommended.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></span></p>
<p>Patients who develop a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> of 100.5°F or greater or other evidence of potential <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> should be instructed to call their physician immediately. </p>
<p>All brand names listed are the registered trademarks of their respective owners and are not trademarks of Teva Pharmaceuticals USA.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_bec5a554-e0e9-4741-8dcd-717c4f54faf0"></a><a name="section-17"></a><p></p>
<h1>PACKAGING INFORMATION </h1>
<p class="First">American Health Packaging unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> (see <a href="#i4i_how_supplied_id_5989ff2e-3757-45cc-a7e7-61f498cef360">How Supplied</a> section) contain drug product from Teva Pharmaceuticals USA, Inc. as follows:</p>
<p>(500 mg / 30 UD) NDC 60687-149-21 packaged from NDC 0093-7474</p>
<p>Packaged and Distributed by:<br><span class="Bold">American Health Packaging</span><br>Columbus, OH 43217</p>
<p>8414921/0515</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="ID_b4559170-3482-4e59-88d3-89c67f660766"></a><a name="section-18"></a><p></p>
<h1>8414921/0515<br>Patient Information</h1>
<p class="First">Capecitabine (KAP e SYE ta been) Tablets USP, Film Coated </p>
<p><span class="Bold">What is the most important information I should know about capecitabine tablets? </span></p>
<p>Capecitabine tablets can cause serious side effects, including: </p>
<dl>
<dt>•</dt>
<dd>Capecitabine tablets can interact with blood thinner medicines, such as warfarin (COUMADIN<span class="Sup">®</span>). Taking capecitabine tablets with these medicines can cause changes in how fast your blood clots, and can cause <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. This can happen as soon as a few days after you start taking capecitabine tablets, or later during treatment, and possibly even within 1 month after you stop taking capecitabine tablets. Your risk may be higher because you have cancer, and if you are over 60 years of age. <dl>
<dt>•</dt>
<dd>Before taking capecitabine tablets, tell your doctor if you are taking warfarin (COUMADIN) or another blood thinner medicine. </dd>
<dt>•</dt>
<dd>If you take warfarin (COUMADIN) or another blood thinner that is like warfarin (COUMADIN) during treatment with capecitabine tablets, your doctor should do blood tests often, to check how fast your blood clots during and after you stop treatment with capecitabine tablets. Your doctor may change your dose of the blood thinner medicine if needed. </dd>
</dl>
</dd>
</dl>
<p>See <span class="Bold">“What are the possible side effects of capecitabine tablets?? </span>for more information about side effects. </p>
<p><span class="Bold">What are capecitabine tablets? </span></p>
<p>Capecitabine tablets are a prescription medicine used to treat people with: </p>
<dl>
<dt>•</dt>
<dd>cancer of the colon that has spread to lymph nodes in the area close to the colon (Dukes’ C stage), after they have surgery. </dd>
<dt>•</dt>
<dd>cancer of the colon or rectum (colorectal) that has spread to other parts of the body (metastatic). </dd>
<dt>•</dt>
<dd>breast cancer that has spread to other parts of the body (metastatic) together with another medicine called docetaxel after treatment with certain other anticancer medicines have not worked. </dd>
<dt>•</dt>
<dd>breast cancer that has spread to other parts of the body and has not improved after treatment with paclitaxel and certain other anti-cancer medicines, or who cannot receive any more treatment with certain anti-cancer medicines. </dd>
</dl>
<p>It is not known if capecitabine tablets are safe and effective in children.</p>
<p><span class="Bold">Who should not take capecitabine tablets? </span></p>
<p>Do not take capecitabine tablets if you: </p>
<dl>
<dt>•</dt>
<dd>have been told that you lack the enzyme DPD (dihydropyrimidine dehydrogenase). </dd>
<dt>•</dt>
<dd>have severe kidney problems. </dd>
<dt>•</dt>
<dd>are allergic to capecitabine, 5-fluorouracil, or any of the ingredients in capecitabine tablets. See the end of this leaflet for a complete list of ingredients in capecitabine tablets. </dd>
</dl>
<p>Talk to your doctor before taking capecitabine tablets if you are not sure if you have any of the conditions listed above. </p>
<p><span class="Bold">What should I tell my doctor before taking capecitabine tablets? </span></p>
<p>See “<span class="Bold">What is the most important information I should know about capecitabine tablets?</span>?. Before you take capecitabine tablets, tell your doctor if you: </p>
<dl>
<dt>•</dt>
<dd>have had heart problems. </dd>
<dt>•</dt>
<dd>have kidney or liver problems. </dd>
<dt>•</dt>
<dd>have any other medical conditions. </dd>
<dt>•</dt>
<dd>are pregnant or plan to become pregnant. Capecitabine tablets can harm your unborn baby. You should not become pregnant during treatment with capecitabine tablets. Talk to your doctor about birth control choices that may be right for you during treatment with capecitabine tablets. </dd>
<dt>•</dt>
<dd>are breastfeeding or plan to breastfeed. It is not known if capecitabine passes into your breast milk. You and your doctor should decide if you will take capecitabine tablets or breastfeed. You should not do both. </dd>
</dl>
<p>Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Capecitabine tablets may affect the way other medicines work, and other medicines may affect the way capecitabine tablets work. </p>
<p>Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine. </p>
<p><span class="Bold">How should I take capecitabine tablets? </span></p>
<dl>
<dt>•</dt>
<dd>Take capecitabine tablets exactly as your doctor tells you to take it. </dd>
<dt>•</dt>
<dd>Your doctor will tell you how many capecitabine tablets to take and when to take them. </dd>
<dt>•</dt>
<dd>Take capecitabine tablets 2 times a day, 1 time in the morning and 1 time in the evening. </dd>
<dt>•</dt>
<dd>Take capecitabine tablets within 30 minutes after finishing a meal. Swallow capecitabine tablets whole with water. Do not crush or cut capecitabine tablets. </dd>
<dt>•</dt>
<dd>Ask your healthcare provider or pharmacist how to safely throw away any unused capecitabine tablets. </dd>
<dt>•</dt>
<dd>If you have side effects with capecitabine tablets, if needed your doctor may decide to: <dl>
<dt>•</dt>
<dd>change your dose of capecitabine tablets</dd>
<dt>•</dt>
<dd>treat you with capecitabine tablets less often </dd>
<dt>•</dt>
<dd>tell you to stop taking capecitabine tablets until certain side effects get better or go away </dd>
<dt>•</dt>
<dd>stop your treatment with capecitabine tablets if you have certain side effects and they are severe </dd>
</dl>
</dd>
<dt>•</dt>
<dd>If you take too many capecitabine tablets, call your doctor or go to the nearest emergency room right away. </dd>
</dl>
<p><span class="Bold">What are the possible side effects of capecitabine tablets? </span></p>
<p>Capecitabine tablets may cause serious side effects including: </p>
<p>See <span class="Bold">“What is the most important information I should know about capecitabine tablets??. </span></p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. </span><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is common with capecitabine tablets and can sometimes be severe. Stop taking capecitabine tablets and call your doctor right away if the number of bowel movements you have in a day increases by 4 or more than is usual for you. Ask your doctor about what medicines you can take to treat your <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. If you have severe <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span> with severe <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, call your doctor or go to the nearest emergency room right away. </dd>
<dt>•</dt>
<dd>
<span class="Bold">heart problems. </span>Capecitabine tablets can cause heart problems including: <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> and decreased blood flow to the heart, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, irregular heartbeats, changes in the electrical activity of your heart seen on an electrocardiogram (ECG), problems with your heart muscle, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, and <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>. Stop taking capecitabine tablets and call your doctor right away if you get any of the following symptoms: <dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> </dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> </dd>
<dt>o</dt>
<dd>feeling <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> </dd>
<dt>o</dt>
<dd>irregular heartbeats or skipping beats </dd>
<dt>o</dt>
<dd>sudden <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> </dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">swollen ankles</span> or legs </dd>
</dl>
</dd>
<dt>•</dt>
<dd><span class="Bold">unexplained <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span> </span></dd>
<dt>•</dt>
<dd><span class="Bold">loss of too much body fluid (<span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>) and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>. </span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span> can happen with capecitabine tablets and may cause sudden <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span> that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. You are at higher risk if you have kidney problems before taking capecitabine tablets and also take other medicines that can cause kidney problems. </dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> are common with capecitabine tablets. If you lose your appetite, feel weak, and have <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, you can quickly become dehydrated. </dd>
<dt> </dt>
<dd>Stop taking capecitabine tablets and call your doctor right away if you: <dl>
<dt>•</dt>
<dd>vomit 2 or more times in a day. </dd>
<dt>•</dt>
<dd>are only able to eat or drink a little now and then, or not at all due to <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. </dd>
<dt>•</dt>
<dd>have <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. See “diarrhea? above. </dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold">serious skin and mouth reactions. </span><dl>
<dt>•</dt>
<dd>Capecitabine tablets can cause serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> that may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Tell your doctor right away if you develop a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> and <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span> of your skin. Your doctor may tell you to stop taking capecitabine tablets if you have a serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span>. Do not take capecitabine tablets again if this happens. </dd>
<dt>•</dt>
<dd>Capecitabine tablets can also cause “hand and foot syndrome.? <span class="product-label-link" type="condition" conceptid="4033054" conceptname="Acral erythema">Hand and foot syndrome</span> is common with capecitabine tablets and can cause you to have <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> and changes in sensation in your hands and feet, or cause <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your hands and feet. Stop taking capecitabine tablets and call your doctor right away if you have any of these symptoms and you are not able to do your usual activities. </dd>
<dt>•</dt>
<dd>you may get sores in your mouth or on your tongue when taking capecitabine tablets. Stop taking capecitabine tablets and call your doctor if you get painful <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, or <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in your mouth and tongue, or if you are having problems eating. Tell your doctor if you have any side effect that bothers you or that does not go away. </dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold">increased level of bilirubin in your blood and liver problems. </span>Increased bilirubin in your blood is common with capecitabine tablets<span class="Bold">. </span>Your doctor will check you for these problems during treatment with capecitabine tablets. </dd>
<dt>•</dt>
<dd>
<span class="Bold">decreased white blood cells, platelets, and red blood cell counts. </span>Your doctor will do blood tests during treatment with capecitabine tablets to check your blood cell counts. </dd>
<dt> </dt>
<dd>If your white blood cell count is very low, you are at increased risk for <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Call your doctor right away if you develop a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> of 100.5<span class="Sup">o</span>F or greater or have other signs and symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. </dd>
</dl>
<p>People 80 years of age or older may be more likely to develop severe or serious side effects with capecitabine tablets. </p>
<p><span class="Bold">The most common side effects of capecitabine tablets include:</span></p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4033054" conceptname="Acral erythema">hand and foot syndrome</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> </dd>
<dt>•</dt>
<dd>stomach-area (abdominal) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> </dd>
<dt>•</dt>
<dd>increased amounts of red blood cell breakdown products (bilirubin) in your blood </dd>
</dl>
<p>These are not all the possible side effects of capecitabine tablets. For more information, ask your doctor or pharmacist. </p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </p>
<p><span class="Bold">How should I store capecitabine tablets? </span></p>
<dl>
<dt>•</dt>
<dd>Store capecitabine tablets at room temperature between 68°F to 77°F (20°C to 25°C).  </dd>
<dt>•</dt>
<dd>Keep capecitabine tablets and all medicines out of the reach of children. </dd>
</dl>
<p><span class="Bold">General information about the safe and effective use of capecitabine tablets. </span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use capecitabine tablets for a condition for which they were not prescribed. Do not give capecitabine tablets to other people, even if they have the same symptoms you have. It may harm them. </p>
<p>You can ask your pharmacist or doctor for information about capecitabine tablets that is written for health professionals. </p>
<p>For more information, call 1-888-838-2872. </p>
<p><span class="Bold">What are the ingredients in capecitabine tablets? </span></p>
<p>Active ingredient: capecitabine </p>
<p>Inactive ingredients: anhydrous lactose, croscarmellose sodium, hypromellose, magnesium stearate, microcrystalline cellulose, red iron oxide, talc, titanium dioxide, and yellow iron oxide. </p>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.</p>
<p>All brand names listed are the registered trademarks of their respective owners and are not trademarks of Teva Pharmaceuticals USA.</p>
<p>Packaged and Distributed by:<br><span class="Bold">American Health Packaging</span><br>Columbus, OH 43217</p>
<p>8414921/0515</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_99e6263e-d1cd-46a5-8a74-fef95664d6fb"></a><a name="section-19"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL </h1>
<div class="Figure">
<a name="id1551573875"></a><img alt="Capecitabine Tablets USP 500 mg Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2777b481-7d7f-461a-b5e0-c09ce2990c34&amp;name=image-08.jpg">
</div>
<p class="First"><span class="Bold">NDC 60687-149-21</span></p>
<p><span class="Bold">CAPECITABINE<br></span>Tablets USP </p>
<p><span class="Bold">500 mg</span></p>
<p><span class="Bold">30 Tablets (3 x 10)</span></p>
<p><span class="Bold">PHARMACIST:</span> Dispense with the accompanying<br>Patient Information Leaflet to each patient.</p>
<p><span class="Bold">Cytotoxic Agent</span></p>
<p><span class="Bold">Each Film-Coated Tablet Contains:</span><br>Capecitabine, USP…………………………………….500 mg</p>
<p><span class="Bold">Usual Dosage:</span> See package insert for full prescribing<br>information.</p>
<p><span class="Bold">Store</span> at 20° to 25°C (68° to 77°F); excursions permitted<br>between 15° to 30°C (59° to 86°F) [see USP Controlled Room<br>Temperature].</p>
<p><span class="Bold">Keep this and all drugs out of reach of children.</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>The drug product contained in this package is from<br>NDC # 0093-7474, Teva Pharmaceuticals USA, Inc.</p>
<p>Packaged and Distributed by:<br>American Health Packaging<br>Columbus, Ohio 43217</p>
<p>714921<br>Rev. 05/2015</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CAPECITABINE 		
					</strong><br><span class="contentTableReg">capecitabine tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60687-149(NDC:0093-7474)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CAPECITABINE</strong> (CAPECITABINE) </td>
<td class="formItem">CAPECITABINE</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (3 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE (peach to light peach) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (oblong) </td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">191;77</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60687-149-21</td>
<td class="formItem">30  in 1 BOX, UNIT-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60687-149-11</td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091649</td>
<td class="formItem">10/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>American Health Packaging
							(929561009)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">American Health Packaging</td>
<td class="formItem"></td>
<td class="formItem">929561009</td>
<td class="formItem">REPACK(60687-149)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>906d97fd-2bc2-44bf-ac2f-b9544897f17f</div>
<div>Set id: 2777b481-7d7f-461a-b5e0-c09ce2990c34</div>
<div>Version: 1</div>
<div>Effective Time: 20150917</div>
</div>
</div> <div class="DistributorName">American Health Packaging</div></p>
</body></html>
